[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Micro-X Ltd.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":197},{"warningLetters":4,"total":196},[5,31,53,77,96,116,135,156,175],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1176,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-11-08T19:00:00Z\">11\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-10T04:00:00Z\">09\u002F10\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicro-x-ltd-692084-09102024\">Micro-X Ltd.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kingsley Hall\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Micro-X Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6 MAB Eastern Promenade, Unit 14\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tonsley\u003C\u002Fspan> \u003Cspan>SA\u003C\u002Fspan> \u003Cspan>5042\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Australia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:khall@micro-x.com\"> khall@micro-x.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 10, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Hall:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Tonsley, South Australia on May 20, 2024, through May 23, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures Micro-X Rover Mobile X-Ray Systems. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received a response from Jolanta Ganzarczyk, dated June 14, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include but are not limited to the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically, your Design Change Control procedure, SOP002, and Design Change Management - Medical Devices, WI002A, address the processing of design changes, the former document requiring a determination of all actions for a design change, including validation and verification. However, multiple design changes were instead processed using Manufacturing Deviation, SOP025-5.1, intended for temporary deviations from manufacturing procedures. For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm’s Manufacturing Deviation Permit, FSOP025A-6.0, stated that these are changes to the product(s) fit, form, or function; the documentation does not include verification\u002Fvalidation results to ensure no adverse effect on the device.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You have planned to update your firm’s procedure for design changes and to train personnel in the verification and validation activities, however, no documentation to this effect has to be presented. As part of the correction, your response does not include\u002Freference a retrospective review of previous design changes to ensure design changes have been properly verified and validated.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Specifically, your firm failed to validate the use and integration of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> software and \u003Cstrong>(b)(4)\u003C\u002Fstrong> panels used in the Micro-X Rover Mobile X-ray System MXU-RV71. Your firm failed to document justification for the decision not to validate.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. In your response, you plan to update the validation plan for MXU-RV71; however, documentation of validation has yet to be provided. Additionally, your response does not include a retrospective review of other design documentation to ensure all designs have been adequately validated.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately establish and maintain procedures for implementing corrective and preventive action (CAPA), as required by 21 CFR 820.100(a). Specifically, Quality Event and CAPA procedure, SOP006, fails to require that appropriate statistical methodology be employed where necessary to detect recurring quality problems, in order to identify existing and potential causes of nonconforming product.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You stated that nonconforming product\u002Fparts are to be investigated and analyzed\u002Ftrended as per SOP005 Control of Nonconforming Product procedure. Specifically, you have planned to review the SOP006 Quality Event &amp; CAPA and include additional sources of quality data. Your firm plans to update the CAPA form to include review of manufacturing records, device history files, and field service tickets when investigating a quality event. No documentation of the planned corrective actions has yet to be provided. However, your firm’s response does not include a retrospective review of quality data using statistical methodology in order to determine whether there exist potential causes of nonconforming product.\u003C\u002Fp>\n\n\u003Cp>4. Failure to adequately ensure complaints are evaluated to determine whether the complaint represents an event which is required to be reported to FDA under 21 CFR Part 803, Medical Device Reporting (MDR), as required by 21 CFR 820.198(a)(3). Specifically, the complaints of reported malfunctions of the Micro-X Rover Mobile X-ray Specifically, the Customer Complaint Form, FSOP007A – 6.0, does not appear to have a field specifying whether the complaint represents an event which is required to be reported to FDA under 21 CFR Part 803. Multiple complaint documents (e.g., CC022-23, CC017-23, CC004-23, CC010-23) did not explicitly include a determination of MDR reportability.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm has planned to update the Customer Complaint Management procedure, and to review previous customer complaints and include a rationale and justification for non-reporting. However, no documentation of the corrective actions has yet to be provided. Additionally, your firm’s corrective action plan does not include employee training.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s Micro-X Rover Mobile X-Ray Systems devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Device; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>5. Failure to report a medical device correction or removal to FDA, initiated to remedy a violation which may present a risk to health, as required by 21 CFR 806.10(a). Specifically, your firm failed to report the following 2 field corrections conducted to reduce a risk to health posed by Micro-X Rover Mobile X-ray Systems:\u003C\u002Fp>\n\n\u003Cp>a. Service Bulletin, SB006-23, for the Micro-X Rover RV19, Micro-X Rover RV35, and Micro-X Rover RV80, was issued to reduce the risk of on-screen keyboard inaccessibility and to ensure the on-screen keyboard will be accessible in other user profiles. Per CAPA024-22, \u003Cstrong>(b)(4)\u003C\u002Fstrong> with Varex, your firm’s software contract manufacturer, to rectify the issue. The CAPA identified the associated risks as an inability to enter patient data, annotate images with text, and configure the system with text.\u003C\u002Fp>\n\n\u003Cp>b. Service Bulletin, SB007-23-1.0, for the Micro-X Rover was issued due to generator failure in extreme humidity environments, which can adversely affect the performance and integrity of the product (e.g., the system may cease to function). Per CAPA024-22, your firm instituted multiple component changes (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) to reduce likelihood of occurrence of the hazard.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You have promised to implement corrective actions such as “[d]evelop a procedure\u002Fwork instruction for issuing Service Bulletins” and “[r]egulatory reporting process for design changes to be developed”. You have also promised to retroactively report the 806 actions to FDA and listed a completion date of September 30, 2024. However, no documentation of the corrections has been provided.\u003C\u002Fp>\n\n\u003Cp>In addition to being a medical device, the mobile X-ray systems are electronic products subject to compliance with Subchapter C of the Act, Electronic Product Radiation Control (EPRC), the requirements at 21 CFR 1000-1005, and the performance standards at 21 CFR 1010 and 1020.30. Your firm failed to comply with the following regulation:\u003C\u002Fp>\n\n\u003Cp>6. Any manufacturer who discovers that any electronic product produced, assembled, or imported by him, which product has left its place of manufacture, has a defect or fails to comply with an applicable Federal standard shall immediately notify the Secretary in accordance with 21 CFR 1003.20, as required by 21 CFR 1003.10(a). Specifically, your firm failed to notify FDA of the following product defects and\u002For failure(s) to comply with an EPRC performance standard, which had resulted in corrective actions for the Micro-X Rover Mobile X-ray Systems:\u003C\u002Fp>\n\n\u003Cp>a. Service Bulletin, SB003-23, covered a firmware update to reduce the risk of repeat exposure due to occurrence of a critical error during short pulse duration exposures with the Micro-X Rover RV35. This is considered a defect per 21 CFR 1003.2(b)(1) in that the product utilizes electronic product radiation to accomplish its primary purpose and from which such emissions are intended, it fails to conform to its design specifications relating to the emission of electronic product radiation.\u003C\u002Fp>\n\n\u003Cp>b. Service Bulletin, SB002-22, covered the installation of an exposure switch holder on the Rover Mobile X-ray to reduce the likelihood of the exposure button being pressed inadvertently while stored. The is considered a defect per 21 CFR 1003.2(b)(1). Any such inadvertent exposure would also be reportable as an Accidental Radiation Occurrence under 21 CFR 1002.20.\u003C\u002Fp>\n\n\u003Cp>c. Modification 017 covered the replacement of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (or earlier) of the Micro-X Rover RV35 and Micro-X Rover RV71 due to a lower post exposure \u003Cstrong>(b)(4)\u003C\u002Fstrong> than the operator’s setting. \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Per 21 CFR 1020.31(a)(4), deviation of technique factors from indicated values shall not exceed the limits given in the information provided in accordance with 21 CFR 1020.30(h)(3).\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You have promised to implement corrective actions such as “Develop a procedure\u002Fwork instruction for issuing Service Bulletins” and “Regulatory reporting process for design changes to be developed”. You have also promised to retroactively report the 806 actions to FDA and listed a completion date of September 30, 2024. However, no documentation of the corrections has been provided.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov.&nbsp;\u003Cstrong>Refer to CMS case #692084 when replying.\u003C\u002Fstrong> If you have any questions about the contents of this letter, please contact: Lu Jiang at lu.jiang@fda.hhs.gov or +1(240)402-5779.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Robert Ochs, Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT8: Office of Radiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cbr>\nGreg Swanson\u003Cbr>\nU.S. Agent\u003Cbr>\nEmergo Global Consulting LLC\u003Cbr>\n2500 Bee Cave Rd., Bldg. 1, Ste. 300\u003Cbr>\nAustin, Texas 78746\u003Cbr>\nUSAgent@ul.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nKingsley Hall\n\nRecipient Title\n\nChief Executive Officer\n\nMicro-X Ltd.\n\n6 MAB Eastern Promenade, Unit 14\n\nTonsley SA 5042\n\nAustralia\n\nkhall@micro-x.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nSeptember 10, 2024\n\nDear Mr. Hall:\n\nDuring an inspection of your firm located in Tonsley, South Australia on May 20, 2024, through May 23, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures Micro-X Rover Mobile X-Ray Systems. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Jolanta Ganzarczyk, dated June 14, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include but are not limited to the following:\n\n1. Failure to adequately establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically, your Design Change Control procedure, SOP002, and Design Change Management - Medical Devices, WI002A, address the processing of design changes, the former document requiring a determination of all actions for a design change, including validation and verification. However, multiple design changes were instead processed using Manufacturing Deviation, SOP025-5.1, intended for temporary deviations from manufacturing procedures. For example, (b)(4). Your firm’s Manufacturing Deviation Permit, FSOP025A-6.0, stated that these are changes to the product(s) fit, form, or function; the documentation does not include verification\u002Fvalidation results to ensure no adverse effect on the device.\n\nWe reviewed your firm’s response and conclude that it is not adequate. You have planned to update your firm’s procedure for design changes and to train personnel in the verification and validation activities, however, no documentation to this effect has to be presented. As part of the correction, your response does not include\u002Freference a retrospective review of previous design changes to ensure design changes have been properly verified and validated.\n\n2. Failure to establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Specifically, your firm failed to validate the use and integration of the (b)(4) software and (b)(4) panels used in the Micro-X Rover Mobile X-ray System MXU-RV71. Your firm failed to document justification for the decision not to validate.\n\nWe reviewed your firm’s response and conclude that it is not adequate. In your response, you plan to update the validation plan for MXU-RV71; however, documentation of validation has yet to be provided. Additionally, your response does not include a retrospective review of other design documentation to ensure all designs have been adequately validated.\n\n3. Failure to adequately establish and maintain procedures for implementing corrective and preventive action (CAPA), as required by 21 CFR 820.100(a). Specifically, Quality Event and CAPA procedure, SOP006, fails to require that appropriate statistical methodology be employed where necessary to detect recurring quality problems, in order to identify existing and potential causes of nonconforming product.\n\nWe reviewed your firm’s response and conclude that it is not adequate. You stated that nonconforming product\u002Fparts are to be investigated and analyzed\u002Ftrended as per SOP005 Control of Nonconforming Product procedure. Specifically, you have planned to review the SOP006 Quality Event & CAPA and include additional sources of quality data. Your firm plans to update the CAPA form to include review of manufacturing records, device history files, and field service tickets when investigating a quality event. No documentation of the planned corrective actions has yet to be provided. However, your firm’s response does not include a retrospective review of quality data using statistical methodology in order to determine whether there exist potential causes of nonconforming product.\n\n4. Failure to adequately ensure complaints are evaluated to determine whether the complaint represents an event which is required to be reported to FDA under 21 CFR Part 803, Medical Device Reporting (MDR), as required by 21 CFR 820.198(a)(3). Specifically, the complaints of reported malfunctions of the Micro-X Rover Mobile X-ray Specifically, the Customer Complaint Form, FSOP007A – 6.0, does not appear to have a field specifying whether the complaint represents an event which is required to be reported to FDA under 21 CFR Part 803. Multiple complaint documents (e.g., CC022-23, CC017-23, CC004-23, CC010-23) did not explicitly include a determination of MDR reportability.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm has planned to update the Customer Complaint Management procedure, and to review previous customer complaints and include a rationale and justification for non-reporting. However, no documentation of the corrective actions has yet to be provided. Additionally, your firm’s corrective action plan does not include employee training.\n\nOur inspection also revealed that your firm’s Micro-X Rover Mobile X-Ray Systems devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Device; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\n\n5. Failure to report a medical device correction or removal to FDA, initiated to remedy a violation which may present a risk to health, as required by 21 CFR 806.10(a). Specifically, your firm failed to report the following 2 field corrections conducted to reduce a risk to health posed by Micro-X Rover Mobile X-ray Systems:\n\na. Service Bulletin, SB006-23, for the Micro-X Rover RV19, Micro-X Rover RV35, and Micro-X Rover RV80, was issued to reduce the risk of on-screen keyboard inaccessibility and to ensure the on-screen keyboard will be accessible in other user profiles. Per CAPA024-22, (b)(4) with Varex, your firm’s software contract manufacturer, to rectify the issue. The CAPA identified the associated risks as an inability to enter patient data, annotate images with text, and configure the system with text.\n\nb. Service Bulletin, SB007-23-1.0, for the Micro-X Rover was issued due to generator failure in extreme humidity environments, which can adversely affect the performance and integrity of the product (e.g., the system may cease to function). Per CAPA024-22, your firm instituted multiple component changes (e.g., (b)(4)) to reduce likelihood of occurrence of the hazard.\n\nWe reviewed your firm’s response and conclude that it is not adequate. You have promised to implement corrective actions such as “[d]evelop a procedure\u002Fwork instruction for issuing Service Bulletins” and “[r]egulatory reporting process for design changes to be developed”. You have also promised to retroactively report the 806 actions to FDA and listed a completion date of September 30, 2024. However, no documentation of the corrections has been provided.\n\nIn addition to being a medical device, the mobile X-ray systems are electronic products subject to compliance with Subchapter C of the Act, Electronic Product Radiation Control (EPRC), the requirements at 21 CFR 1000-1005, and the performance standards at 21 CFR 1010 and 1020.30. Your firm failed to comply with the following regulation:\n\n6. Any manufacturer who discovers that any electronic product produced, assembled, or imported by him, which product has left its place of manufacture, has a defect or fails to comply with an applicable Federal standard shall immediately notify the Secretary in accordance with 21 CFR 1003.20, as required by 21 CFR 1003.10(a). Specifically, your firm failed to notify FDA of the following product defects and\u002For failure(s) to comply with an EPRC performance standard, which had resulted in corrective actions for the Micro-X Rover Mobile X-ray Systems:\n\na. Service Bulletin, SB003-23, covered a firmware update to reduce the risk of repeat exposure due to occurrence of a critical error during short pulse duration exposures with the Micro-X Rover RV35. This is considered a defect per 21 CFR 1003.2(b)(1) in that the product utilizes electronic product radiation to accomplish its primary purpose and from which such emissions are intended, it fails to conform to its design specifications relating to the emission of electronic product radiation.\n\nb. Service Bulletin, SB002-22, covered the installation of an exposure switch holder on the Rover Mobile X-ray to reduce the likelihood of the exposure button being pressed inadvertently while stored. The is considered a defect per 21 CFR 1003.2(b)(1). Any such inadvertent exposure would also be reportable as an Accidental Radiation Occurrence under 21 CFR 1002.20.\n\nc. Modification 017 covered the replacement of (b)(4) (or earlier) of the Micro-X Rover RV35 and Micro-X Rover RV71 due to a lower post exposure (b)(4) than the operator’s setting. (b)(4). Per 21 CFR 1020.31(a)(4), deviation of technique factors from indicated values shall not exceed the limits given in the information provided in accordance with 21 CFR 1020.30(h)(3).\n\nWe reviewed your firm’s response and conclude that it is not adequate. You have promised to implement corrective actions such as “Develop a procedure\u002Fwork instruction for issuing Service Bulletins” and “Regulatory reporting process for design changes to be developed”. You have also promised to retroactively report the 806 actions to FDA and listed a completion date of September 30, 2024. However, no documentation of the corrections has been provided.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case #692084 when replying. If you have any questions about the contents of this letter, please contact: Lu Jiang at lu.jiang@fda.hhs.gov or +1(240)402-5779.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nRobert Ochs, Ph.D.\n\nDirector\n\nOHT8: Office of Radiological Health\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nGreg Swanson\n\nU.S. Agent\n\nEmergo Global Consulting LLC\n\n2500 Bee Cave Rd., Bldg. 1, Ste. 300\n\nAustin, Texas 78746\n\nUSAgent@ul.com","Micro-X Ltd.","micro-x-ltd-692084-09102024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicro-x-ltd-692084-09102024","2026-10-26T08:09:24.735845+00:00","Warning Letter","Issued","2024-11-08","692084","Medical Devices","Kingsley Hall","2026-08-19T19:14:31.925+00:00","Via Email","2024-09-10",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":18,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":47,"closeout_date":19,"issuing_office":37,"recipient_name":48,"body_fetched_at":49,"delivery_method":50,"recipient_title":19,"reference_number":51,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},1131,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2024-12-17T14:20:00Z\">12\u002F17\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-03T05:00:00Z\">12\u002F03\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicro-orgo-chem-686458-12032024\">Micro Orgo Chem\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-21\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Vinod Ranka\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Micro Orgo Chem\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>57, C-1B, LIC sector, GIDC\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Vapi\u003C\u002Fspan> \u003Cspan>396195\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gujarat\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@mocind.com\"> info@mocind.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-21\u003C\u002Fp>\u003Cp>December 3, 2024\u003Cbr>\u003Cbr>Dear Mr. Ranka:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Micro Orgo Chem, 3004513977, at 57, C-1\u002FB, LIC sector, GIDC, VAPI, 396195, Gujarat, from April 11 to 18, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your May 3, 2024 response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific deviations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to adequately validate written procedures for the cleaning and maintenance of equipment.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately validate cleaning procedures for your non-dedicated manufacturing equipment to ensure it is fit for its intended use. You also failed to properly maintain your equipment as they were observed to be in a state of disrepair.\u003C\u002Fp>\u003Cp>Your quality assurance personnel stated that your firm has not carried out cleaning validation for non-dedicated manufacturing equipment routinely used for the manufacture of intermediates and APIs for the U.S. market. Additionally, you failed to follow established cleaning procedures. Your firm was unable to demonstrate rinse and swab samples were collected and tested as required by your procedure. Furthermore, \u003Cstrong>(b)(4)\u003C\u002Fstrong>-03 and other equipment used to manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong> appeared dirty and not appropriately maintained. A failure to adequately clean and maintain non-dedicated equipment may lead to cross-contamination between drug products.\u003C\u002Fp>\u003Cp>In your response, you acknowledge “the facility was not maintained to uphold the sanitary conditions required for manufacturing and laboratory areas” and you commit to voluntarily recall all APIs shipped to the U.S. market. You also commit to initiate a change control to include a protocol-based cleaning validation in your procedures and to train personnel to document the cleaning and release of equipment.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide a cleaning validation protocol and a revised equipment maintenance plan to ensure your APIs are free from cross-contamination.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>&nbsp; o Drugs with higher toxicities\u003Cbr>&nbsp; o Drugs with higher drug potencies\u003Cbr>&nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>&nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>&nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>&nbsp; o Maximum hold times before cleaning\u003Cbr>• A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003Cbr>• A comprehensive evaluation of your facility cleaning and maintenance program. Also provide your CAPA plan to improve routine cleaning and preventative maintenance at your facility.\u003Cbr>• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to demonstrate your manufacturing process can reproducibly produce an API that meets its predetermined quality attributes. Also, there is no assurance that your facilities, equipment, and testing methods are suitable for their intended use.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to establish a protocol and implement a plan to ensure all API manufacturing processes, equipment and facilities are fit for use. For example,\u003C\u002Fp>\u003Cp>• Your firm could not provide records that process performance qualification (PPQ) had been performed for any of your APIs (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) manufacturing processes.\u003Cbr>• Your firm had not adequately qualified equipment used to manufacture APIs and could not provide records confirming that your API manufacturing equipment would operate as intended.\u003Cbr>• Your firm failed to ensure that test methods used were suitable for their intended use as in-house methods were not validated and USP methods were not verified.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately to assure the quality of raw material inputs, in-process materials, and finished APIs. Process qualification studies determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful PPQ studies incorporating the use of appropriately qualified equipment and validated test methods are necessary prior to commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. Failure to implement adequate analytical method validation practices can result in insufficient understanding of process variables or failure to detect a drift in capability, which increases the risk of drug quality defects.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>In your response, you commit to issuing a CAPA to review the instrument qualification process, qualify all equipment for your new facility and verify that process methods and specifications are approved before starting operations at your new facility.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not commit to performing an assessment of the impact of using non-validated processes, equipment, test methods and systems on APIs already distributed to the United States. Additionally, you fail to provide a detailed PPQ protocol for conducting validation activities.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003Cbr>• A timeline for performing PPQ for each of your marketed drugs.\u003Cbr>• Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003Cbr>• A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility. Improved procedures regarding validation\u002Fverification requirements and updated analytical methods.\u003Cbr>• An independent, retrospective review of results obtained using unverified\u002Funvalidated compendial and non-compendial methods.\u003Cbr>• A summary of the impact assessment for released batches.\u003Cbr>• A comprehensive, independent review of your laboratory practices, methods, equipment, and analyst competencies. Based on this review, provide a detailed CAPA plan to fully remediate your laboratory system.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to design a documented, on-going stability testing program to monitor the stability characteristics of API and to use the results to confirm appropriate storage conditions and retest or expiry dates.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s stability program was inadequate. Your firm failed to place at least one batch of each API manufactured in 2021, 2022, and 2023 on stability. Additionally, there were no stability chambers nor stability and reserve samples available at your facility.\u003C\u002Fp>\u003Cp>In your response, you indicate that stability studies are conducted in accordance with your SOP and that your stability chambers were recently moved. You also state that new stability chambers are under qualification at your new facility for future production.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide any records that ongoing stability studies are conducted and reserve samples could be located and tested to ensure expiry and retest dates are valid.\u003C\u002Fp>\u003Cp>In response to this letter, please provide the following:\u003C\u002Fp>\u003Cp>• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>&nbsp; o Stability indicating methods.\u003Cbr>&nbsp; o Stability studies for each drug in its marketed container-closure system before distribution is permitted.\u003Cbr>&nbsp; o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>&nbsp; o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003Cbr>&nbsp; o All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to prepare, review, and approve documents related to the manufacturing of API in accordance with written procedures.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to document all CGMP related manufacturing activities at the time they were performed. Our investigator observed numerous unlabeled \u003Cstrong>(b)(4)\u003C\u002Fstrong> drums in your manufacturing areas. Your personnel indicated these drums contained \u003Cstrong>(b)(4)\u003C\u002Fstrong> from various processes but were unable to identify what products and processes they were associated with. In addition, you failed to maintain original batch records for APIs produced at your facility. For example, the batch record for \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> with an expiry date of March 2024 was requested and not available. This batch was released and shipped to the U.S. market, prior to the start of our inspection.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that quality related activities were not recorded at the time of performance. You commit to issue a deviation to amend your procedure for preparing master formulas and batch manufacturing records to include language requiring all production-related activities be recorded at the time they are performed. In addition, you commit to conduct training on the amended procedures and to perform a retrospective review of batch records to ensure all activities are documented.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide sufficient detail regarding your corrective actions and preventive actions (CAPAs). In addition, you do not specify any verification activities to ensure the effectiveness of the procedural revisions and training. You also do not describe how you will perform the retrospective review of batch records.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, contemporaneous, original, and accurate records throughout your operation.\u003Cbr>&nbsp; o In addition to interim data retention measures, also provide more comprehensive and sustainable CAPA for retention of all CGMP data. This includes provisions that address not only the need to retain batch-related data for appropriate periods, but also the long-term retention of all source data from development studies that support design, qualification, validation, and application.\u003Cbr>&nbsp; o A detailed summary of your procedural updates and associated training, including but not limited to, document retention.\u003Cbr>&nbsp; o A detailed summary of how you intend to assess CAPA effectiveness.\u003Cbr>• An independent retrospective review of your drug production records for all batches distributed to the United States and that remain within expiry. Your assessment should include a determination of whether appropriate documentation (e.g., manufacturing records, testing records, distribution records) is available to ensure ongoing CGMP compliance. Specify actions you will take in response to the retrospective review, such as customer notifications and recalls.\u003Cbr>&nbsp; o Provide a summary report of all API batches released that may still remain on the market where a supporting batch record could not be located. Include a summary of any measures you will take to ensure these batches meet the required expiry or any testing protocols performed to support the expiry date of these drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure of your quality unit to exercise its responsibility to ensure the API manufactured at your facility are in compliance with CGMP.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s quality unit (QU) failed to perform routine QU functions to ensure drug manufacturing operations were adequate. For example, your QU failed to:\u003C\u002Fp>\u003Cp>• Follow your change control procedure for drugs shipped to the United States. You failed to evaluate the use of different \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing process through your established procedure.\u003Cbr>• Perform annual product reviews for APIs manufactured from 2020 to 2024.\u003Cbr>• Ensure proper documentation was maintained for raw material release and critical deviations, including out-of-specifications and laboratory investigations.\u003C\u002Fp>\u003Cp>In your response, you acknowledge annual product reviews and specific change controls and deviations were not initiated due to an oversight by the QU and commit to initiate a deviation. Additionally, you commit to retrain your current quality personnel.\u003C\u002Fp>\u003Cp>Your response is inadequate. You fail to commit to performing a risk assessment of your QU. Furthermore, you fail to explain how initiating deviations will adequately remediate your QU deficiencies.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003Cbr>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>&nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all drugs.\u003Cbr>&nbsp; o Also describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003Cbr>• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your QU. Your change management program should also include provisions for determining change effectiveness.\u003Cbr>• A plan to ensure that you will complete, and document adequately, product quality reviews at least annually for all APIs.\u003Cbr>• Procedures for investigating, responding to, and correcting any deviations from quality and safety standards identified as a part of your product quality review findings and risk assessments.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the deviations identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligations to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Recall and Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On April 15, 2024, during the inspection, you communicated your commitment to cease manufacturing and distribution of all drugs for the U.S. market. You also informed the Agency of your decision to deregister until your new facility is qualified, and to voluntarily recall all drugs within expiry in current distribution in the United States.\u003C\u002Fp>\u003Cp>On September 18, 2024, the FDA held a teleconference to inquire about the steps taken to initiate your voluntary recall. The agency recommended a recall of all drugs currently in distribution from the U.S. market.\u003C\u002Fp>\u003Cp>Despite numerous attempts by the Agency to obtain recall information, you have not provided complete documentation regarding your efforts to voluntarily recall all drugs distributed to the United States.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPAs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\u003Cp>FDA placed products offered for import into the United States from your firm on Import Alert 66-40 on October 22, 2024.\u003C\u002Fp>\u003Cp>Correct any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any deviations.\u003C\u002Fp>\u003Cp>Failure to address any deviations may also result in the FDA continuing to refuse admission of articles manufactured at Micro Orgo Chem 57, C-1B, LIC sector, GIDC, Vapi, 396195, Gujarat, India, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004513977 and ATTN: Marva Taylor.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-25-21\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Vinod Ranka\n\nRecipient Title\n\nManaging Director\n\nMicro Orgo Chem\n\n57, C-1B, LIC sector, GIDC\n\nVapi 396195\n\nGujarat\n\nIndia\n\ninfo@mocind.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-21\nDecember 3, 2024\n\nDear Mr. Ranka:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Micro Orgo Chem, 3004513977, at 57, C-1\u002FB, LIC sector, GIDC, VAPI, 396195, Gujarat, from April 11 to 18, 2024.\nThis warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your May 3, 2024 response to our Form FDA 483 in detail.\nDuring our inspection, our investigator observed specific deviations including, but not limited to, the following.\n1. Failure to adequately validate written procedures for the cleaning and maintenance of equipment.\nYou failed to adequately validate cleaning procedures for your non-dedicated manufacturing equipment to ensure it is fit for its intended use. You also failed to properly maintain your equipment as they were observed to be in a state of disrepair.\nYour quality assurance personnel stated that your firm has not carried out cleaning validation for non-dedicated manufacturing equipment routinely used for the manufacture of intermediates and APIs for the U.S. market. Additionally, you failed to follow established cleaning procedures. Your firm was unable to demonstrate rinse and swab samples were collected and tested as required by your procedure. Furthermore, (b)(4)-03 and other equipment used to manufacture (b)(4) appeared dirty and not appropriately maintained. A failure to adequately clean and maintain non-dedicated equipment may lead to cross-contamination between drug products.\nIn your response, you acknowledge “the facility was not maintained to uphold the sanitary conditions required for manufacturing and laboratory areas” and you commit to voluntarily recall all APIs shipped to the U.S. market. You also commit to initiate a change control to include a protocol-based cleaning validation in your procedures and to train personnel to document the cleaning and release of equipment.\nYour response is inadequate. You do not provide a cleaning validation protocol and a revised equipment maintenance plan to ensure your APIs are free from cross-contamination.\nIn response to this letter, provide:\n• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher drug potencies\no Drugs of lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning\n• A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n• A comprehensive evaluation of your facility cleaning and maintenance program. Also provide your CAPA plan to improve routine cleaning and preventative maintenance at your facility.\n• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n2. Failure to demonstrate your manufacturing process can reproducibly produce an API that meets its predetermined quality attributes. Also, there is no assurance that your facilities, equipment, and testing methods are suitable for their intended use.\nYour firm failed to establish a protocol and implement a plan to ensure all API manufacturing processes, equipment and facilities are fit for use. For example,\n• Your firm could not provide records that process performance qualification (PPQ) had been performed for any of your APIs (e.g., (b)(4)) manufacturing processes.\n• Your firm had not adequately qualified equipment used to manufacture APIs and could not provide records confirming that your API manufacturing equipment would operate as intended.\n• Your firm failed to ensure that test methods used were suitable for their intended use as in-house methods were not validated and USP methods were not verified.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately to assure the quality of raw material inputs, in-process materials, and finished APIs. Process qualification studies determine whether an initial state of control has been established.\nSuccessful PPQ studies incorporating the use of appropriately qualified equipment and validated test methods are necessary prior to commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. Failure to implement adequate analytical method validation practices can result in insufficient understanding of process variables or failure to detect a drift in capability, which increases the risk of drug quality defects.\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn your response, you commit to issuing a CAPA to review the instrument qualification process, qualify all equipment for your new facility and verify that process methods and specifications are approved before starting operations at your new facility.\nYour response is inadequate. You do not commit to performing an assessment of the impact of using non-validated processes, equipment, test methods and systems on APIs already distributed to the United States. Additionally, you fail to provide a detailed PPQ protocol for conducting validation activities.\nIn response to this letter, provide:\n• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n• A timeline for performing PPQ for each of your marketed drugs.\n• Process performance protocol(s), and written procedures for qualification of equipment and facilities.\n• A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility. Improved procedures regarding validation\u002Fverification requirements and updated analytical methods.\n• An independent, retrospective review of results obtained using unverified\u002Funvalidated compendial and non-compendial methods.\n• A summary of the impact assessment for released batches.\n• A comprehensive, independent review of your laboratory practices, methods, equipment, and analyst competencies. Based on this review, provide a detailed CAPA plan to fully remediate your laboratory system.\n3. Failure to design a documented, on-going stability testing program to monitor the stability characteristics of API and to use the results to confirm appropriate storage conditions and retest or expiry dates.\nYour firm’s stability program was inadequate. Your firm failed to place at least one batch of each API manufactured in 2021, 2022, and 2023 on stability. Additionally, there were no stability chambers nor stability and reserve samples available at your facility.\nIn your response, you indicate that stability studies are conducted in accordance with your SOP and that your stability chambers were recently moved. You also state that new stability chambers are under qualification at your new facility for future production.\nYour response is inadequate. You do not provide any records that ongoing stability studies are conducted and reserve samples could be located and tested to ensure expiry and retest dates are valid.\nIn response to this letter, please provide the following:\n• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods.\no Stability studies for each drug in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\no Detailed definition of the specific attributes to be tested at each station (timepoint).\no All procedures that describe these and other elements of your remediated stability program.\n4. Failure to prepare, review, and approve documents related to the manufacturing of API in accordance with written procedures.\nYou failed to document all CGMP related manufacturing activities at the time they were performed. Our investigator observed numerous unlabeled (b)(4) drums in your manufacturing areas. Your personnel indicated these drums contained (b)(4) from various processes but were unable to identify what products and processes they were associated with. In addition, you failed to maintain original batch records for APIs produced at your facility. For example, the batch record for (b)(4) batch (b)(4) with an expiry date of March 2024 was requested and not available. This batch was released and shipped to the U.S. market, prior to the start of our inspection.\nIn your response, you acknowledge that quality related activities were not recorded at the time of performance. You commit to issue a deviation to amend your procedure for preparing master formulas and batch manufacturing records to include language requiring all production-related activities be recorded at the time they are performed. In addition, you commit to conduct training on the amended procedures and to perform a retrospective review of batch records to ensure all activities are documented.\nYour response is inadequate. You do not provide sufficient detail regarding your corrective actions and preventive actions (CAPAs). In addition, you do not specify any verification activities to ensure the effectiveness of the procedural revisions and training. You also do not describe how you will perform the retrospective review of batch records.\nIn response to this letter, provide the following:\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, contemporaneous, original, and accurate records throughout your operation.\no In addition to interim data retention measures, also provide more comprehensive and sustainable CAPA for retention of all CGMP data. This includes provisions that address not only the need to retain batch-related data for appropriate periods, but also the long-term retention of all source data from development studies that support design, qualification, validation, and application.\no A detailed summary of your procedural updates and associated training, including but not limited to, document retention.\no A detailed summary of how you intend to assess CAPA effectiveness.\n• An independent retrospective review of your drug production records for all batches distributed to the United States and that remain within expiry. Your assessment should include a determination of whether appropriate documentation (e.g., manufacturing records, testing records, distribution records) is available to ensure ongoing CGMP compliance. Specify actions you will take in response to the retrospective review, such as customer notifications and recalls.\no Provide a summary report of all API batches released that may still remain on the market where a supporting batch record could not be located. Include a summary of any measures you will take to ensure these batches meet the required expiry or any testing protocols performed to support the expiry date of these drugs.\n5. Failure of your quality unit to exercise its responsibility to ensure the API manufactured at your facility are in compliance with CGMP.\nYour firm’s quality unit (QU) failed to perform routine QU functions to ensure drug manufacturing operations were adequate. For example, your QU failed to:\n• Follow your change control procedure for drugs shipped to the United States. You failed to evaluate the use of different (b)(4) in your (b)(4) manufacturing process through your established procedure.\n• Perform annual product reviews for APIs manufactured from 2020 to 2024.\n• Ensure proper documentation was maintained for raw material release and critical deviations, including out-of-specifications and laboratory investigations.\nIn your response, you acknowledge annual product reviews and specific change controls and deviations were not initiated due to an oversight by the QU and commit to initiate a deviation. Additionally, you commit to retrain your current quality personnel.\nYour response is inadequate. You fail to commit to performing a risk assessment of your QU. Furthermore, you fail to explain how initiating deviations will adequately remediate your QU deficiencies.\nIn response to this letter, provide:\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all drugs.\no Also describe how top management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your QU. Your change management program should also include provisions for determining change effectiveness.\n• A plan to ensure that you will complete, and document adequately, product quality reviews at least annually for all APIs.\n• Procedures for investigating, responding to, and correcting any deviations from quality and safety standards identified as a part of your product quality review findings and risk assessments.\nCGMP Consultant Recommended\nBased upon the nature of the deviations identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligations to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nDrug Recall and Production Suspended\nOn April 15, 2024, during the inspection, you communicated your commitment to cease manufacturing and distribution of all drugs for the U.S. market. You also informed the Agency of your decision to deregister until your new facility is qualified, and to voluntarily recall all drugs within expiry in current distribution in the United States.\nOn September 18, 2024, the FDA held a teleconference to inquire about the steps taken to initiate your voluntary recall. The agency recommended a recall of all drugs currently in distribution from the U.S. market.\nDespite numerous attempts by the Agency to obtain recall information, you have not provided complete documentation regarding your efforts to voluntarily recall all drugs distributed to the United States.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPAs.\nConclusion\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\nFDA placed products offered for import into the United States from your firm on Import Alert 66-40 on October 22, 2024.\nCorrect any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any deviations.\nFailure to address any deviations may also result in the FDA continuing to refuse admission of articles manufactured at Micro Orgo Chem 57, C-1B, LIC sector, GIDC, Vapi, 396195, Gujarat, India, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004513977 and ATTN: Marva Taylor.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Micro Orgo Chem","micro-orgo-chem-686458-12032024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicro-orgo-chem-686458-12032024","2026-10-26T08:09:24.66393+00:00","2024-12-17","686458","Drugs","Mr. Vinod Ranka","2026-08-19T17:07:57.694+00:00","VIA EMAIL WITH READ RECEIPT","320-25-21","2024-12-03",{"id":54,"raw":55,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":23,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":19,"issuing_office":59,"recipient_name":72,"body_fetched_at":73,"delivery_method":74,"recipient_title":19,"reference_number":75,"action_taken_date":76,"medical_device_id":19,"response_letter_date":19},1567,[56,57,58,59,60,13,13,13],"\u003Ctime datetime=\"2024-03-12T13:20:00Z\">03\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-09T05:00:00Z\">02\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhuman-microbes-672740-02092024\">Human Microbes\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","CGMP\u002FDeviations\u002FBiologics License Application (BLA)\u003Cbr \u002F>\r\n","CGMP\u002FDeviations\u002FBiologics License Application (BLA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail \n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER-24-672740\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael J. Harrop\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Human Microbes\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3870 La Sierra Avenue #1069\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Riverside\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92505\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:michael@humanmicrobes.org\"> michael@humanmicrobes.org\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter #CBER-24-672740\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: February 09, 202\u003Cbr>\n\u003Cbr>\nDear Mr. Harrop:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at www.humanmicrobes.org in February 2024, which contains instructions on how to buy fecal microbiota for transplantation (FMT) (hereinafter, “your products”). Your website indicates that you are offering for sale (in the United States, Canada, and other parts of the world) FMT in various forms (e.g., capsules, enemas, and infusions) for the treatment or prevention of various diseases or conditions. For example, your website states the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“FMT is a lifesaving treatment for the deadly gut infection Clostridium Difficile (C. Diff) and has shown promising results in clinical trials for many other conditions [1], such as IBS (\u003Cem>irritable bowel syndrome\u003C\u002Fem>), IBD (\u003Cem>inflammatory bowel disease\u003C\u002Fem>), Parkinson’s disease, fibromyalgia, chronic fatigue syndrome (CFS), multiple sclerosis, autism, diabetes, and mental health disorders like depression, anxiety, and bipolar.”\u003C\u002Fli>\n\t\u003Cli>“FMT may also have potential applications in the treatment of obesity, autoimmunity, cardiovascular disease, cancer, and more.”\u003C\u002Fli>\n\t\u003Cli>“FMT is also a treatment option to attenuate adverse effects associated with antibiotic use.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your YouTube channel (https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=jPRg-_voHXQ) has a video titled, “We want your poop” that contains the following statements:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“FMTs offer a potential new treatment option for a long list of conditions…including irritable bowel syndrome, obesity and even mental disorders.”\u003C\u002Fli>\n\t\u003Cli>Refers to a patient “cured her bipolar disorder after receiving an FMT”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Because these statements indicate that your products are intended for use in the mitigation, treatment, or prevention of disease, they are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 321(g)(1)(B)]. Your products are also “new drugs” under section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective (GRASE) for their labeled uses. Additionally, your products are biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. § 262(i)] because they are applicable to the prevention, treatment, or cure of a disease or condition of human beings.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is also a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. A biological product for which a BLA has been approved under 42 U.S.C. § 262(a) is not required to have an approved application under section 505 of the FD&amp;C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in 21 U.S.C. § 355(a). While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312]. Your products are not the subject of an approved BLA or an approved application under 21 U.S.C. § 355. In addition, there is no IND in effect for their use. Therefore, your products are both unapproved new drugs and unlicensed biological products. Furthermore, based on the statements on your website, you cause the introduction or delivery for introduction into interstate commerce of your products in violation of the FD&amp;C Act [21 U.S.C. § 331(d)].\u003C\u002Fp>\n\n\u003Cp>We note that your website references an “FDA enforcement discretion policy” regarding FMT. In November 2022, FDA issued a revised guidance titled, “\u003Cu>Enforcement Policy Regarding Investigational New Drugs Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridioides difficile Infection Not Responsive to Standard Therapies\u003C\u002Fu>”. This guidance document indicates that FDA intends to exercise enforcement discretion regarding the IND requirements for the use of FMT in treating \u003Cem>Clostridioides difficile (C. difficile)\u003C\u002Fem> infection not responding to standard therapies, where, among other things, the stool donor and stool are qualified by screening and testing performed under the direction of the licensed health care provider for the purpose of providing the FMT product to treat his or her patient and use of the FMT product does not raise reported safety concerns or potential significant safety concerns.\u003C\u002Fp>\n\n\u003Cp>Based on a review of your website, you offer FMT for treatment of diseases and conditions other than \u003Cem>C. difficile\u003C\u002Fem> infection. As noted in FDA’s November 2022 guidance, data related to the use and study of FMT to treat diseases or conditions other than \u003Cem>C. difficile\u003C\u002Fem> infection not responding to standard therapies are more limited, and study of FMT for other uses is not included in the aforementioned enforcement policy. In addition, although your website recommends that patients “discuss their plans with their doctor,” it offers your products directly to patients, including for self-administration. For example, your website indicates that donors can ship your products directly to patients and provides instructions on methods of self-administration. Therefore, there is no assurance that a licensed health care provider treating each of these patients is directing the screening and testing of the stool donor and stool for the patient, as described in the November 2022 guidance. Your products also raise potential significant safety concerns due to inadequate donor screening. We also note the reported safety concerns described in the “donor results spreadsheet” on your website (e.g., “increased intestinal pain, nausea, sweating, and loss of appetite among other things”). For these reasons, your products would not fall within the enforcement discretion policy referenced above.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for promptly investigating and determining the causes of any violations, correcting them, and preventing their recurrence, and ensuring full compliance with the law.\u003C\u002Fp>\n\n\u003Cp>We advise you to comprehensively review your website and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&amp;C Act, the PHS Act, and their implementing regulations. Failure to adequately address this matter may result in enforcement action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your products are not in violation of the FD&amp;C Act and the PHS Act, include your reasoning and any supporting information for our consideration in your response to this letter.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Melissa J. Mendoza\u003Cbr>\nDirector, Office of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FMT is a live biotherapeutic product composed of microorganisms. Microorganisms are not human cells or tissues and do not meet the definition of HCT\u002FP (see 21 CFR 1271.3(d)).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER-24-672740\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMichael J. Harrop\n\nRecipient Title\n\nFounder\n\nHuman Microbes\n\n3870 La Sierra Avenue #1069\n\nRiverside, CA 92505\n\nUnited States\n\nmichael@humanmicrobes.org\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nWarning Letter #CBER-24-672740\n\nDate: February 09, 202\n\nDear Mr. Harrop:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at www.humanmicrobes.org in February 2024, which contains instructions on how to buy fecal microbiota for transplantation (FMT) (hereinafter, “your products”). Your website indicates that you are offering for sale (in the United States, Canada, and other parts of the world) FMT in various forms (e.g., capsules, enemas, and infusions) for the treatment or prevention of various diseases or conditions. For example, your website states the following:\n\n“FMT is a lifesaving treatment for the deadly gut infection Clostridium Difficile (C. Diff) and has shown promising results in clinical trials for many other conditions [1], such as IBS (irritable bowel syndrome), IBD (inflammatory bowel disease), Parkinson’s disease, fibromyalgia, chronic fatigue syndrome (CFS), multiple sclerosis, autism, diabetes, and mental health disorders like depression, anxiety, and bipolar.”\n\n“FMT may also have potential applications in the treatment of obesity, autoimmunity, cardiovascular disease, cancer, and more.”\n\n“FMT is also a treatment option to attenuate adverse effects associated with antibiotic use.”\n\nAdditionally, your YouTube channel (https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=jPRg-_voHXQ) has a video titled, “We want your poop” that contains the following statements:\n\n“FMTs offer a potential new treatment option for a long list of conditions…including irritable bowel syndrome, obesity and even mental disorders.”\n\nRefers to a patient “cured her bipolar disorder after receiving an FMT”\n\nBecause these statements indicate that your products are intended for use in the mitigation, treatment, or prevention of disease, they are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 321(g)(1)(B)]. Your products are also “new drugs” under section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective (GRASE) for their labeled uses. Additionally, your products are biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. § 262(i)] because they are applicable to the prevention, treatment, or cure of a disease or condition of human beings.1\n\nPlease be advised that to lawfully market a drug that is also a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. A biological product for which a BLA has been approved under 42 U.S.C. § 262(a) is not required to have an approved application under section 505 of the FD&C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in 21 U.S.C. § 355(a). While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312]. Your products are not the subject of an approved BLA or an approved application under 21 U.S.C. § 355. In addition, there is no IND in effect for their use. Therefore, your products are both unapproved new drugs and unlicensed biological products. Furthermore, based on the statements on your website, you cause the introduction or delivery for introduction into interstate commerce of your products in violation of the FD&C Act [21 U.S.C. § 331(d)].\n\nWe note that your website references an “FDA enforcement discretion policy” regarding FMT. In November 2022, FDA issued a revised guidance titled, “Enforcement Policy Regarding Investigational New Drugs Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridioides difficile Infection Not Responsive to Standard Therapies”. This guidance document indicates that FDA intends to exercise enforcement discretion regarding the IND requirements for the use of FMT in treating Clostridioides difficile (C. difficile) infection not responding to standard therapies, where, among other things, the stool donor and stool are qualified by screening and testing performed under the direction of the licensed health care provider for the purpose of providing the FMT product to treat his or her patient and use of the FMT product does not raise reported safety concerns or potential significant safety concerns.\n\nBased on a review of your website, you offer FMT for treatment of diseases and conditions other than C. difficile infection. As noted in FDA’s November 2022 guidance, data related to the use and study of FMT to treat diseases or conditions other than C. difficile infection not responding to standard therapies are more limited, and study of FMT for other uses is not included in the aforementioned enforcement policy. In addition, although your website recommends that patients “discuss their plans with their doctor,” it offers your products directly to patients, including for self-administration. For example, your website indicates that donors can ship your products directly to patients and provides instructions on methods of self-administration. Therefore, there is no assurance that a licensed health care provider treating each of these patients is directing the screening and testing of the stool donor and stool for the patient, as described in the November 2022 guidance. Your products also raise potential significant safety concerns due to inadequate donor screening. We also note the reported safety concerns described in the “donor results spreadsheet” on your website (e.g., “increased intestinal pain, nausea, sweating, and loss of appetite among other things”). For these reasons, your products would not fall within the enforcement discretion policy referenced above.\n\nThe violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for promptly investigating and determining the causes of any violations, correcting them, and preventing their recurrence, and ensuring full compliance with the law.\n\nWe advise you to comprehensively review your website and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&C Act, the PHS Act, and their implementing regulations. Failure to adequately address this matter may result in enforcement action without further notice, including, without limitation, seizure and\u002For injunction.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your products are not in violation of the FD&C Act and the PHS Act, include your reasoning and any supporting information for our consideration in your response to this letter.\n\nWithin fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\n\nYour written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMelissa J. Mendoza\n\nDirector, Office of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\n_______________________\n\n1 FMT is a live biotherapeutic product composed of microorganisms. Microorganisms are not human cells or tissues and do not meet the definition of HCT\u002FP (see 21 CFR 1271.3(d)).","Human Microbes","human-microbes-672740-02092024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhuman-microbes-672740-02092024","2026-10-26T08:08:56.778732+00:00","2024-03-12","672740","Biologics","Michael J. Harrop","2026-08-20T00:14:31.434+00:00","VIA UPS and Electronic Mail","CBER-24-672740","2024-02-09",{"id":78,"raw":79,"subject":12,"body_html":83,"body_text":84,"firm_name":85,"letter_id":86,"created_at":87,"fei_number":19,"letter_url":88,"updated_at":89,"action_type":22,"case_status":23,"posted_date":90,"marcs_cms_no":91,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":92,"body_fetched_at":93,"delivery_method":94,"recipient_title":19,"reference_number":19,"action_taken_date":95,"medical_device_id":19,"response_letter_date":19},898,[80,81,82,11,12,13,13,13],"\u003Ctime datetime=\"2025-05-20T04:00:00Z\">05\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-05-08T04:00:00Z\">05\u002F08\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrospecialties-llc-707614-05082025\">Microspecialties, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gaston S. Levesque\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Microspecialties, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>430 Smith Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Middletown\u003C\u002Fspan>, \u003Cspan>CT\u003C\u002Fspan> \u003Cspan>06457\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:steven.levesque@microspecialties.com\"> steven.levesque@microspecialties.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 707614\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 8, 2025\u003C\u002Fp>\u003Cp>Dear Gaston S. Levesque:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Middletown, CT, from January 14, 2025, through February 18, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm contract manufactures Class I and II ophthalmic surgical devices such as sterile I-PACK injection kits, punctum plugs, and microkeratome blades. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Rick Brinsmade, Quality Assurance and Regulatory Affairs (QA\u002FRA) Manager, dated March 4, 2025 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR 820.80(d).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 6.13 of your “Sterilization Process Control” procedure (QA-0041; Rev 3; Effective: 1\u002F27\u002F23) which requires release of sterile products to inventory via Form 0070 once accompanying dosimetry records and certificates of processing (COPs) are received back from the contract sterilizer. For example, you stated that Form 0070 was never utilized to release \u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes of I-PACK injection kits (Lot #: P62764979R, P63044983R, P62764965R and P62764970R) into inventory because you fabricated the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization COPs (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) as if they originated from the customer-approved contract sterilizer. Subsequently, on 03\u002F21\u002F24, your Director of Quality Assurance released the above nonconforming lots of I-PACK injection kits, which are intended for administration of intravitreal injections during eye surgery, as sterile to your customer on 3\u002F12\u002F24 despite never shipping these products to the customer-approved contract sterilizer (or elsewhere) for sterilization. This event resulted in a Class II recall RES 94794 initiated by your firm on 6\u002F5\u002F24 followed up by a Class I recall by your customer on \u003Cstrong>(b)(4)\u003C\u002Fstrong> under RES \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The adequacy of the response dated 3\u002F4\u002F25 cannot be determined at this time. Under CAR # 1288 (2\u002F20\u002F25) opened to address the failure to follow QA-0041, you reference CAR # 1261 (5\u002F31\u002F24) for the root cause which pointed to limited resources, lack of effectiveness of training, storage of product in a non-routine location, and lack of \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization labels. Corrective actions included notification of the nonconforming lots to your customer upon discovery of the error; replacement of your Director of Quality Assurance with a new Quality Assurance and Regulatory Affairs Manager; addition of \u003Cstrong>(b)(4)\u003C\u002Fstrong> exposure indication dots to shipping cartons; update of Form 0070 to include verification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> indicator dot color changes; update of QA-0041 to restrict product release to QA, President, or Administrative Assistant; update the training procedure (QA-0019) to include effectiveness tests, including a test for sterilization processes; and retrospective review of sterilization and release documentations to verify accuracy. Under CAR # 1289 (2\u002F20\u002F25) opened to address release of nonconforming product, you also reference the root cause(s) and several of the corrective actions above under CAR # 1261 and note additional completed actions which included the requirement for \u003Cstrong>(b)(4)\u003C\u002Fstrong> irradiation exposure dots on shipping cartons and process specifications for your new contract sterilizer in QA-0041; addition of integrity requirements to the document, part number, and data control procedure (QA-0020); and a new code of conduct and ethics procedure (QA-0099) for which all employees completed training. By 6\u002F1\u002F25, you plan to also add irradiation exposure dots to each individual carton of trays and microkeratome blades. Please provide updates on the progress of these corrective actions and corrections, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically:\u003C\u002Fp>\u003Cp>a. You failed to implement sections 5.1.2 and 5.2.1 of your “Process Validation” procedure (QA-0063; Effective: 11\u002F8\u002F23) which requires that Operations (with input from Quality) determine “***\u003Cem>if re-validation is needed for changes to validation manufacturing processes\u003C\u002Fem>***” and that Quality “***\u003Cem>Reviews and approves the assessments of validation needs and revalidation determinations\u003C\u002Fem>***,” respectively. For example, you authorized the release of lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 9\u002F4\u002F24; \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 10\u002F14\u002F24; and \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 11\u002F19\u002F24, containing medical devices, such as punctum plugs, customized injection trays, microkeratome blades, microkeratome tubing, and ophthalmic convenience kits, for distribution without documented justification for why a revalidation was not required, prior to switching to a new contract sterilizer for \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization of such devices on 3\u002F19\u002F24.\u003C\u002Fp>\u003Cp>b. You failed to implement sections 1.0 and 2.0 of your “Process Validation” procedure (QA-0063; Effective: 11\u002F8\u002F23) which require validations of processes related to inventory items such as “***\u003Cem>a component, material, assembly, packaging, and labeling that is part or will become part of the finished medical device including the finished medical device\u003C\u002Fem>***.” For example, you did not conduct a validation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection method outlined in section 6.1.2 of the “Seal Inspection” procedure (QA-0042; Effective: 6\u002F30\u002F24) for testing the seal integrity of sterile pouches containing Microkeratome Blades, to ensure that manufacturing employees are able to repeatably and reproducibly able to detect conforming and nonconforming seal pouches with a high degree of assurance as a part of finished device acceptance. These devices are indicated for use during LASIK surgery to shave tissue from sections of the cornea for a lamellar (partial thickness) transplant.\u003C\u002Fp>\u003Cp>The response dated 3\u002F4\u002F25 is not adequate. Under CAR # 1290 (2\u002F20\u002F25) initiated to address release of sterile products prior to conducting a revalidation for the new contract sterilizer, you state that management did not believe that a revalidation was required because the new contract \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilizer was able to sterilize the product with the specified dose mapping and dose audits and bioburden testing continued. In addition, you point out that your newly hired QA\u002FRA manager determined that a retrospective validation was required such that a comprehensive validation was conducted and formally approved on 12\u002F16\u002F24. However, there were no corrective actions identified to address the primary issue which is that you did not follow your procedure to review and approve your decision not to revalidate the sterilization process at the time these products were released for distribution.\u003C\u002Fp>\u003Cp>With regards to the lack of test method validation for the seal integrity inspection, you state that you will write a formal process adoption by analyzing the data outputs from the seal validations by 5\u002F1\u002F25. However, there were no corrective actions identified to review whether any other test methods require process validations to demonstrate that that you are able to consistently detect conforming and nonconforming product with a high degree of assurance. Therefore, please provide a response on how you plan to address the above deficiencies.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to ensure that sampling plans are written and based on a valid statistical rationale when used, as required by 820.250(b).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you acknowledged there was no statistical rationale documented for the sampling plan in section 6.1.2 of the “Seal Inspection” procedure (QA-0042; Effective: 6\u002F30\u002F24) to inspect the first \u003Cstrong>(b)(4)\u003C\u002Fstrong> pouches for seal integrity.\u003C\u002Fp>\u003Cp>The response dated 3\u002F4\u002F25 is not adequate. Under CAR # 1290 (2\u002F20\u002F25) initiated to address the lack of test method validation for the seal integrity inspection as well as failure to provide statistically supported evidence when sampling, you state that you will write a formal process adoption by analyzing the data outputs from the seal validations by 5\u002F1\u002F25. However, there were no corrective actions identified to address the concerns relating to lack of valid statistical rationale for the sampling plan employed during sealing inspections of sterile pouches. Therefore, please provide a response on how you plan to address the above deficiencies.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 707614” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Rick Brinsmade, QA\u002FRA Manager, rick@pro-paks.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nGaston S. Levesque\n\nRecipient Title\n\nPresident and CEO\n\nMicrospecialties, LLC\n\n430 Smith Street\n\nMiddletown, CT 06457\n\nUnited States\n\nsteven.levesque@microspecialties.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 707614\nMay 8, 2025\nDear Gaston S. Levesque:\nDuring an inspection of your firm located in Middletown, CT, from January 14, 2025, through February 18, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm contract manufactures Class I and II ophthalmic surgical devices such as sterile I-PACK injection kits, punctum plugs, and microkeratome blades. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Rick Brinsmade, Quality Assurance and Regulatory Affairs (QA\u002FRA) Manager, dated March 4, 2025 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR 820.80(d).\nSpecifically, you failed to implement section 6.13 of your “Sterilization Process Control” procedure (QA-0041; Rev 3; Effective: 1\u002F27\u002F23) which requires release of sterile products to inventory via Form 0070 once accompanying dosimetry records and certificates of processing (COPs) are received back from the contract sterilizer. For example, you stated that Form 0070 was never utilized to release (b)(4) boxes of I-PACK injection kits (Lot #: P62764979R, P63044983R, P62764965R and P62764970R) into inventory because you fabricated the (b)(4) sterilization COPs ((b)(4) and (b)(4)) as if they originated from the customer-approved contract sterilizer. Subsequently, on 03\u002F21\u002F24, your Director of Quality Assurance released the above nonconforming lots of I-PACK injection kits, which are intended for administration of intravitreal injections during eye surgery, as sterile to your customer on 3\u002F12\u002F24 despite never shipping these products to the customer-approved contract sterilizer (or elsewhere) for sterilization. This event resulted in a Class II recall RES 94794 initiated by your firm on 6\u002F5\u002F24 followed up by a Class I recall by your customer on (b)(4) under RES (b)(4).\nThe adequacy of the response dated 3\u002F4\u002F25 cannot be determined at this time. Under CAR # 1288 (2\u002F20\u002F25) opened to address the failure to follow QA-0041, you reference CAR # 1261 (5\u002F31\u002F24) for the root cause which pointed to limited resources, lack of effectiveness of training, storage of product in a non-routine location, and lack of (b)(4) sterilization labels. Corrective actions included notification of the nonconforming lots to your customer upon discovery of the error; replacement of your Director of Quality Assurance with a new Quality Assurance and Regulatory Affairs Manager; addition of (b)(4) exposure indication dots to shipping cartons; update of Form 0070 to include verification of (b)(4) indicator dot color changes; update of QA-0041 to restrict product release to QA, President, or Administrative Assistant; update the training procedure (QA-0019) to include effectiveness tests, including a test for sterilization processes; and retrospective review of sterilization and release documentations to verify accuracy. Under CAR # 1289 (2\u002F20\u002F25) opened to address release of nonconforming product, you also reference the root cause(s) and several of the corrective actions above under CAR # 1261 and note additional completed actions which included the requirement for (b)(4) irradiation exposure dots on shipping cartons and process specifications for your new contract sterilizer in QA-0041; addition of integrity requirements to the document, part number, and data control procedure (QA-0020); and a new code of conduct and ethics procedure (QA-0099) for which all employees completed training. By 6\u002F1\u002F25, you plan to also add irradiation exposure dots to each individual carton of trays and microkeratome blades. Please provide updates on the progress of these corrective actions and corrections, including any supporting evidence.\n2. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\nSpecifically:\na. You failed to implement sections 5.1.2 and 5.2.1 of your “Process Validation” procedure (QA-0063; Effective: 11\u002F8\u002F23) which requires that Operations (with input from Quality) determine “***if re-validation is needed for changes to validation manufacturing processes***” and that Quality “***Reviews and approves the assessments of validation needs and revalidation determinations***,” respectively. For example, you authorized the release of lots (b)(4) on 9\u002F4\u002F24; (b)(4) on 10\u002F14\u002F24; and (b)(4) on 11\u002F19\u002F24, containing medical devices, such as punctum plugs, customized injection trays, microkeratome blades, microkeratome tubing, and ophthalmic convenience kits, for distribution without documented justification for why a revalidation was not required, prior to switching to a new contract sterilizer for (b)(4) sterilization of such devices on 3\u002F19\u002F24.\nb. You failed to implement sections 1.0 and 2.0 of your “Process Validation” procedure (QA-0063; Effective: 11\u002F8\u002F23) which require validations of processes related to inventory items such as “***a component, material, assembly, packaging, and labeling that is part or will become part of the finished medical device including the finished medical device***.” For example, you did not conduct a validation of the (b)(4) inspection method outlined in section 6.1.2 of the “Seal Inspection” procedure (QA-0042; Effective: 6\u002F30\u002F24) for testing the seal integrity of sterile pouches containing Microkeratome Blades, to ensure that manufacturing employees are able to repeatably and reproducibly able to detect conforming and nonconforming seal pouches with a high degree of assurance as a part of finished device acceptance. These devices are indicated for use during LASIK surgery to shave tissue from sections of the cornea for a lamellar (partial thickness) transplant.\nThe response dated 3\u002F4\u002F25 is not adequate. Under CAR # 1290 (2\u002F20\u002F25) initiated to address release of sterile products prior to conducting a revalidation for the new contract sterilizer, you state that management did not believe that a revalidation was required because the new contract (b)(4) sterilizer was able to sterilize the product with the specified dose mapping and dose audits and bioburden testing continued. In addition, you point out that your newly hired QA\u002FRA manager determined that a retrospective validation was required such that a comprehensive validation was conducted and formally approved on 12\u002F16\u002F24. However, there were no corrective actions identified to address the primary issue which is that you did not follow your procedure to review and approve your decision not to revalidate the sterilization process at the time these products were released for distribution.\nWith regards to the lack of test method validation for the seal integrity inspection, you state that you will write a formal process adoption by analyzing the data outputs from the seal validations by 5\u002F1\u002F25. However, there were no corrective actions identified to review whether any other test methods require process validations to demonstrate that that you are able to consistently detect conforming and nonconforming product with a high degree of assurance. Therefore, please provide a response on how you plan to address the above deficiencies.\n3. Failure to ensure that sampling plans are written and based on a valid statistical rationale when used, as required by 820.250(b).\nSpecifically, you acknowledged there was no statistical rationale documented for the sampling plan in section 6.1.2 of the “Seal Inspection” procedure (QA-0042; Effective: 6\u002F30\u002F24) to inspect the first (b)(4) pouches for seal integrity.\nThe response dated 3\u002F4\u002F25 is not adequate. Under CAR # 1290 (2\u002F20\u002F25) initiated to address the lack of test method validation for the seal integrity inspection as well as failure to provide statistically supported evidence when sampling, you state that you will write a formal process adoption by analyzing the data outputs from the seal validations by 5\u002F1\u002F25. However, there were no corrective actions identified to address the concerns relating to lack of valid statistical rationale for the sampling plan employed during sealing inspections of sterile pouches. Therefore, please provide a response on how you plan to address the above deficiencies.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 707614” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Rick Brinsmade, QA\u002FRA Manager, rick@pro-paks.com","Microspecialties, LLC","microspecialties-llc-707614-05082025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrospecialties-llc-707614-05082025","2026-10-26T08:09:24.836404+00:00","2025-05-20","707614","Gaston S. Levesque","2026-08-19T16:46:07.915+00:00","VIA Electronic Mail","2025-05-08",{"id":97,"raw":98,"subject":61,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":106,"fei_number":19,"letter_url":107,"updated_at":108,"action_type":22,"case_status":23,"posted_date":109,"marcs_cms_no":110,"product_type":71,"closeout_date":19,"issuing_office":59,"recipient_name":111,"body_fetched_at":112,"delivery_method":113,"recipient_title":19,"reference_number":114,"action_taken_date":115,"medical_device_id":19,"response_letter_date":19},417,[99,100,101,59,61,13,13,13],"\u003Ctime datetime=\"2025-12-16T05:00:00Z\">12\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-03T05:00:00Z\">12\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrovascular-tissue-inc-710860-12032025\">Microvascular Tissue, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-710860\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Glen G. Gong, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Microvascular Tissue, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6199 Cornerstone Court East, Suite 109\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Diego\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92121\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ggong@mvtissues.com\"> ggong@mvtissues.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 3, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 25-710860\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Dr. Gong:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between March 31, 2025, and April 8, 2025. During the inspection, FDA documented that your company markets and distributes a product derived from hypodermis that you recover from donors, and marketed as mVASC® (hereinafter, “mVASC” or “your product”), for allogeneic use. Your firm has a contract with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, for them to manufacture mVASC and you also participate in its manufacture.\u003C\u002Fp>\u003Cp>This letter is to advise you that your product is an unapproved new drug in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C § 355(a). Your product is also an unlicensed biological product in violation of section\u003Cbr>351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your introduction or delivery for introduction of your product into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>This warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211 in the manufacture of your product. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your product is adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your product into interstate commerce, or the causing thereof is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. § 331(a).&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product Violations\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your website, www.mvtissues.com, last visited December 2025, your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Your website states that “mVASC is intended for the repair, reconstruction, replacement, or supplementation of damaged extracellular matrix (ECM) in skin defects that extend through the dermis into and\u002For through the hypodermis.”\u003C\u002Fli>\u003Cli>Your website’s title tag states, “MicroVascular Tissues – Healing Vascular Deficiences [sic].”\u003C\u002Fli>\u003Cli>Your tissue distributor training presentation titled “mVASC Wound Applications”, dated March 2025 states, “mVASC healed 74% of DFUs [Diabetic Foot Ulcers] at 12 weeks versus 38% for SOC [Standard of Care].”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your product is a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).&nbsp;\u003C\u002Fp>\u003Cp>Your product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Microvascular Tissues, Inc. does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all criteria in 21 CFR 1271.10(a).&nbsp;\u003C\u002Fp>\u003Cp>Because the hypodermis that you recover from donors is predominantly composed of adipocytes and surrounding connective tissues that mainly function to provide physical cushioning and support to the body, FDA considers the hypodermis to be a structural tissue for the purpose of applying the regulatory framework. Under the 21 CFR part 1271 regulatory framework, a structural tissue is minimally manipulated if the processing does not alter the original relevant characteristics of the tissue relating to the tissue’s utility for reconstruction, repair, or replacement. 21 CFR 1271.3(f)(1). Thus, whether processing of hypodermis would meet the regulatory definition of minimal manipulation takes into consideration whether the processing alters the original relevant characteristics of the hypodermis related to its utility to provide cushioning and support to the body.&nbsp;\u003C\u002Fp>\u003Cp>Your product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of hypodermal tissue related to its utility for reconstruction, repair, or replacement. Hypodermis tissue (i.e., subcutaneous layer comprising adipose tissue) is processed by your firm using \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong>, thus altering the structure of the extracellular matrix.&nbsp;\u003C\u002Fp>\u003Cp>In addition, your mVASC product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) &amp; 1271.10(a)(2). Your hypodermis (i.e., subcutaneous layer comprising adipose tissue) derived ECM product is not intended to perform the same basic function or functions in the recipient as in the donor (e.g., providing cushioning and support to the body). Rather, the use of your product for repair, reconstruction, replacement, or supplementation of damaged ECM in skin defects that extend through the dermis into and\u002For through the hypodermis is not a basic function of hypodermis in the donor (e.g., providing cushioning and support to the body). In contrast to that basic function, mVASC is instead intended to facilitate the healing of full thickness skin wounds via revascularization which would require the biochemical stimulation of a wound healing response in the body via cell signaling. This is a non-homologous use for hypodermis tissue.&nbsp;\u003C\u002Fp>\u003Cp>Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your product is regulated as a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your product is not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483).\u003C\u002Fp>\u003Cp>The CGMP violations applicable to your product include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess, as required by 21 CFR 211.100(a).\u003C\u002Fstrong> You have not validated the manufacturing process for your product with respect to identity, strength, quality, and purity. For example:\u003C\u002Fp>\u003Cp>a. Your firm has not validated critical manufacturing steps for your product, including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> using \u003Cstrong>(b)(4)\u003C\u002Fstrong> with the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>b. Your firm has not performed a process validation since moving the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to a new contract manufacturer in November 2018.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to conduct at least one test to verify the identity of each component of a drug product, using specific identity tests if they exist, as required by 21 CFR 211.84(d)(1).\u003C\u002Fstrong> Identity testing is not performed on each component used in the manufacturing of mVASC, for example \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>\u003Cstrong>Response to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your response, dated April 29, 2025, to FDA’s Form FDA-483 in detail. Your response is inadequate to address the violations noted above. For example, your response does not adequately address your firm’s continued manufacture and distribution of your product or your plans for disposition of your current inventory manufactured under the violative conditions outlined above. Additionally, you do not describe actions you have taken or plan to take that adequately address the impact of the above-noted deficiencies on your distributed product that carries an \u003Cstrong>(b)(4)\u003C\u002Fstrong> shelf life and was manufactured under the above-described conditions.\u003C\u002Fp>\u003Cp>Your firm’s response repeatedly asserts that your product should be regulated solely under section 361 of the PHS Act, and that the violations noted above are not applicable to your product. Based on your position, you have not adequately proposed corrective actions which address the CGMP violations noted above. While you assert that your product should be regulated solely under section 361 of the PHS Act, as explained above, the available evidence shows that your product does not meet all criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271.\u003C\u002Fp>\u003Cp>As such, your response further does not adequately address your lack of an approved BLA to lawfully market your product. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect. 42 U.S.C. 262(a). Such licenses are issued only after showing that the product is safe, pure, and potent.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your product is in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>Cc: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>______________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA. Guidance for Industry and Food and Drug Administration Staff. Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. July 2020. https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F109176\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Because your product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 25-710860\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nGlen G. Gong, PhD\n\nRecipient Title\n\nChief Executive Officer\n\nMicrovascular Tissue, Inc.\n\n6199 Cornerstone Court East, Suite 109\n\nSan Diego, CA 92121\n\nUnited States\n\nggong@mvtissues.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nDecember 3, 2025\nCBER 25-710860\nDear Dr. Gong:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between March 31, 2025, and April 8, 2025. During the inspection, FDA documented that your company markets and distributes a product derived from hypodermis that you recover from donors, and marketed as mVASC® (hereinafter, “mVASC” or “your product”), for allogeneic use. Your firm has a contract with (b)(4), for them to manufacture mVASC and you also participate in its manufacture.\nThis letter is to advise you that your product is an unapproved new drug in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C § 355(a). Your product is also an unlicensed biological product in violation of section\n351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your product into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nThis warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211 in the manufacture of your product. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your product is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your product into interstate commerce, or the causing thereof is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a).\nUnapproved New Drug and Unlicensed Biological Product Violations\nBased on information and records reviewed by FDA, including your website, www.mvtissues.com, last visited December 2025, your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example:\nYour website states that “mVASC is intended for the repair, reconstruction, replacement, or supplementation of damaged extracellular matrix (ECM) in skin defects that extend through the dermis into and\u002For through the hypodermis.”\nYour website’s title tag states, “MicroVascular Tissues – Healing Vascular Deficiences [sic].”\nYour tissue distributor training presentation titled “mVASC Wound Applications”, dated March 2025 states, “mVASC healed 74% of DFUs [Diabetic Foot Ulcers] at 12 weeks versus 38% for SOC [Standard of Care].”\nTherefore, your product is a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Microvascular Tissues, Inc. does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all criteria in 21 CFR 1271.10(a).\nBecause the hypodermis that you recover from donors is predominantly composed of adipocytes and surrounding connective tissues that mainly function to provide physical cushioning and support to the body, FDA considers the hypodermis to be a structural tissue for the purpose of applying the regulatory framework. Under the 21 CFR part 1271 regulatory framework, a structural tissue is minimally manipulated if the processing does not alter the original relevant characteristics of the tissue relating to the tissue’s utility for reconstruction, repair, or replacement. 21 CFR 1271.3(f)(1). Thus, whether processing of hypodermis would meet the regulatory definition of minimal manipulation takes into consideration whether the processing alters the original relevant characteristics of the hypodermis related to its utility to provide cushioning and support to the body.\nYour product fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of hypodermal tissue related to its utility for reconstruction, repair, or replacement. Hypodermis tissue (i.e., subcutaneous layer comprising adipose tissue) is processed by your firm using (b)(4).1 (b)(4), thus altering the structure of the extracellular matrix.\nIn addition, your mVASC product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) & 1271.10(a)(2). Your hypodermis (i.e., subcutaneous layer comprising adipose tissue) derived ECM product is not intended to perform the same basic function or functions in the recipient as in the donor (e.g., providing cushioning and support to the body). Rather, the use of your product for repair, reconstruction, replacement, or supplementation of damaged ECM in skin defects that extend through the dermis into and\u002For through the hypodermis is not a basic function of hypodermis in the donor (e.g., providing cushioning and support to the body). In contrast to that basic function, mVASC is instead intended to facilitate the healing of full thickness skin wounds via revascularization which would require the biochemical stimulation of a wound healing response in the body via cell signaling. This is a non-homologous use for hypodermis tissue.\nTherefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.2 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your product is regulated as a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your product is not the subject of an approved BLA.\nCGMP Violations\nFDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483).\nThe CGMP violations applicable to your product include, but are not limited to, the following:\n1. Failure to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess, as required by 21 CFR 211.100(a). You have not validated the manufacturing process for your product with respect to identity, strength, quality, and purity. For example:\na. Your firm has not validated critical manufacturing steps for your product, including the (b)(4) using (b)(4) with the (b)(4).\nb. Your firm has not performed a process validation since moving the “(b)(4)” to a new contract manufacturer in November 2018.\n2. Failure to conduct at least one test to verify the identity of each component of a drug product, using specific identity tests if they exist, as required by 21 CFR 211.84(d)(1). Identity testing is not performed on each component used in the manufacturing of mVASC, for example (b)(4).\nResponse to the Form FDA-483\nWe have reviewed your response, dated April 29, 2025, to FDA’s Form FDA-483 in detail. Your response is inadequate to address the violations noted above. For example, your response does not adequately address your firm’s continued manufacture and distribution of your product or your plans for disposition of your current inventory manufactured under the violative conditions outlined above. Additionally, you do not describe actions you have taken or plan to take that adequately address the impact of the above-noted deficiencies on your distributed product that carries an (b)(4) shelf life and was manufactured under the above-described conditions.\nYour firm’s response repeatedly asserts that your product should be regulated solely under section 361 of the PHS Act, and that the violations noted above are not applicable to your product. Based on your position, you have not adequately proposed corrective actions which address the CGMP violations noted above. While you assert that your product should be regulated solely under section 361 of the PHS Act, as explained above, the available evidence shows that your product does not meet all criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271.\nAs such, your response further does not adequately address your lack of an approved BLA to lawfully market your product. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect. 42 U.S.C. 262(a). Such licenses are issued only after showing that the product is safe, pure, and potent.\nConclusion\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your product is in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\nCc: (b)(4)\n______________________________\n1 FDA. Guidance for Industry and Food and Drug Administration Staff. Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. July 2020. https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F109176\u002Fdownload.\n2 Because your product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","Microvascular Tissue, Inc.","microvascular-tissue-inc-710860-12032025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrovascular-tissue-inc-710860-12032025","2026-10-26T08:09:24.878769+00:00","2025-12-16","710860","Glen G. Gong, PhD","2026-08-19T16:09:12.895+00:00","Via UPS and EMAIL","CBER 25-710860","2025-12-03",{"id":117,"raw":118,"subject":122,"body_html":123,"body_text":124,"firm_name":125,"letter_id":126,"created_at":127,"fei_number":19,"letter_url":128,"updated_at":129,"action_type":22,"case_status":23,"posted_date":130,"marcs_cms_no":131,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":132,"body_fetched_at":133,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":134,"medical_device_id":19,"response_letter_date":19},3496,[119,120,121,11,122,13,13,13],"\u003Ctime datetime=\"2021-03-02T15:00:00Z\">03\u002F02\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-25T05:00:00Z\">01\u002F25\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fenmed-microanalytics-inc-610131-01252021\">EnMed MicroAnalytics, Inc.\u003C\u002Fa>","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Edwin Naylor\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>EnMed MicroAnalytics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>645 Meeting St, Suite 2\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Charleston\u003C\u002Fspan>, \u003Cspan>SC\u003C\u002Fspan> \u003Cspan>29403-4279\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@enmedmicroanalytics.com\"> info@enmedmicroanalytics.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: January 25, 2021\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fenmedmicroanalytics.com on October 8, 2020. FDA has observed that your website offers sample collection kits that instructs individuals to send a blood or saliva sample to you for COVID-19\u003Csup>\u003Cstrong>[1]\u003C\u002Fstrong>\u003C\u002Fsup> serology or molecular testing, specifically the “COVID-19 BLOOD SPOT COLLECTION PACKET” and the “SARS-CoV-2 SALIVA RT-PCR TEST COLLECTION PACKET” (collectively referred to as “Sample Collection Kits”). Based on our review, these products are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>The “Sample Collection Kits” are offered for sale and distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cstrong>[2]\u003C\u002Fstrong>\u003C\u002Fsup> In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.\u003Csup>\u003Cstrong>[3]\u003C\u002Fstrong>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you offer for sale products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate corrective action to prevent the sale of any unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Your websites, https:\u002F\u002Fenmedmicroanalytics.com and https:\u002F\u002Ffacebook.com\u002FEnMedMicroAnalytics\u002F indicate that the “COVID-19 BLOOD SPOT COLLECTION PACKET” is intended to be used for at-home blood sample collection for COVID-19 serology testing, including:\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cstrong>[4]\u003C\u002Fstrong>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to immediately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraudscams\u002F fraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and such actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken appropriate corrective action.\u003C\u002Fp>\n\n\u003Cp>If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Timothy Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics and Radiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>_____________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>[1]\u003C\u002Fstrong> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>[2]\u003C\u002Fstrong> Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists. Jan. 31, 2020. (Accessible at&nbsp;https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx). The declaration has been renewed for an additional 90 days three times. The most recent renewal went into effect on October 23, 2020. Secretary of Health and Human Services Alex M. Azar II, Renewal of Determination that a Public Health Emergency Exists. October 2, 2020. (Accessible at&nbsp;https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fcovid19-2Oct2020.aspx;).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>[3]\u003C\u002Fstrong> President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19). Mar. 13, 2020. (Accessible at https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidentialactions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>[4]\u003C\u002Fstrong> Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nEdwin Naylor\n\nEnMed MicroAnalytics, Inc.\n\n645 Meeting St, Suite 2\n\nCharleston, SC 29403-4279\n\nUnited States\n\ninfo@enmedmicroanalytics.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDate: January 25, 2021\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fenmedmicroanalytics.com on October 8, 2020. FDA has observed that your website offers sample collection kits that instructs individuals to send a blood or saliva sample to you for COVID-19[1] serology or molecular testing, specifically the “COVID-19 BLOOD SPOT COLLECTION PACKET” and the “SARS-CoV-2 SALIVA RT-PCR TEST COLLECTION PACKET” (collectively referred to as “Sample Collection Kits”). Based on our review, these products are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nThe “Sample Collection Kits” are offered for sale and distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.[2] In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.[3] Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you offer for sale products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate corrective action to prevent the sale of any unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nYour websites, https:\u002F\u002Fenmedmicroanalytics.com and https:\u002F\u002Ffacebook.com\u002FEnMedMicroAnalytics\u002F indicate that the “COVID-19 BLOOD SPOT COLLECTION PACKET” is intended to be used for at-home blood sample collection for COVID-19 serology testing, including:\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”[4] provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to immediately address this matter may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraudscams\u002F fraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and such actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken appropriate corrective action.\n\nIf you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics and Radiological Health\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n_____________________________________\n\n[1] As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n[2] Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists. Jan. 31, 2020. (Accessible at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx). The declaration has been renewed for an additional 90 days three times. The most recent renewal went into effect on October 23, 2020. Secretary of Health and Human Services Alex M. Azar II, Renewal of Determination that a Public Health Emergency Exists. October 2, 2020. (Accessible at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fcovid19-2Oct2020.aspx;).\n\n[3] President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19). Mar. 13, 2020. (Accessible at https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidentialactions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F).\n\n[4] Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","EnMed MicroAnalytics, Inc.","enmed-microanalytics-inc-610131-01252021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fenmed-microanalytics-inc-610131-01252021","2026-10-26T08:08:35.68476+00:00","2021-03-02","610131","Edwin Naylor","2026-08-20T03:19:50.048+00:00","2021-01-25",{"id":136,"raw":137,"subject":12,"body_html":142,"body_text":143,"firm_name":144,"letter_id":145,"created_at":146,"fei_number":19,"letter_url":147,"updated_at":148,"action_type":22,"case_status":149,"posted_date":150,"marcs_cms_no":151,"product_type":26,"closeout_date":152,"issuing_office":11,"recipient_name":153,"body_fetched_at":154,"delivery_method":94,"recipient_title":19,"reference_number":19,"action_taken_date":155,"medical_device_id":19,"response_letter_date":19},2214,[138,139,140,11,12,13,141,13],"\u003Ctime datetime=\"2023-02-07T14:20:00Z\">02\u002F07\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-30T04:00:00Z\">09\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrovention-costa-rica-srl-643188-09302022\">MicroVention Costa Rica S.R.L.\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrovention-costa-rica-srl-643188-09162025\">\u003Ctime datetime=\"2025-11-17T05:00:00Z\">11\u002F17\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Charlie Noel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>SVP, International Operations-CR\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>MicroVention Costa Rica S.R.L.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Coyol Free Zone, B 33 Zona Franca Coyol, Edificio B33\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>El Coyol De Alajuela\u003C\u002Fspan>, \u003Cspan>Alajuela\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>20101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Costa Rica\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 30, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Charlie Noel:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Alajuela, Costa Rica, on May 23, 2022, through May 26, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Headway Microcatheter, LVIS, LVIS Jr, Scepter C and XC Occlusion Balloon Catheter, SOFIA Catheters, and BOBBY Balloon Guide Catheter. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received responses from Scafford Serron, Ph.D., VP of Global Quality dated June 16, 2022, July 18, 2022, and August 18, 2022, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1.&nbsp;Failure to verify a process that cannot be fully verified by subsequent inspection and test with a high degree of assurance and approved according to established procedures. The validation activities and results, including the date and signature of the individual(s) approving the validation and where appropriate the major equipment validated, shall be documented, as required by 21 CFR 820.75(a) – Process Validation. For example:\u003C\u002Fp>\n\n\u003Cp>a. The catheter wash limitation process justifications \u003Cstrong>(b)(4)\u003C\u002Fstrong> dated October 31,2018 and \u003Cstrong>(b)(4)\u003C\u002Fstrong> dated June 10, 2021, do not specify the requirements for the catheter wash process validation prior to conducting the process validation. Additionally, the justifications provided for several test parameters do not provide a high degree of assurance and were not approved according to established procedures. Prior to the 2018 validation, this process had not been validated according to established procedures. Therefore, it is unknown if the catheter wash process sufficiently removes foreign material from the manufacturing process.\u003C\u002Fp>\n\n\u003Cp>The responses dated June 16, 2022, July 18, 2022, and August 18, 2022 are not adequate. Your firm initiated CAPA\u003Cstrong>(b)(4)\u003C\u002Fstrong> to address Observation 1 and identified four root causes and training corrective actions, and conducted a retrospective review of processes requiring validation. Documents gathered at the inspection, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and provided in the response, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>(b)(4)\u003C\u002Fstrong> require biocompatibility testing comply with ISO 10993-1. However, CAPA\u003Cstrong>(b)(4)\u003C\u002Fstrong> does not provide a high degree of assurance, as addressed in the FDA-recognized standard ISO-10993 [Biocompatibility]. For example:\u003C\u002Fp>\n\n\u003Cp>i)&nbsp; Per Part 1 of ISO-10993, a gap analysis and selection of biological endpoints for assessment is necessary to assess the biological safety of the medical device. The proposed responses and corrective actions do not address all biological endpoints, including pyrogenicity.\u003C\u002Fp>\n\n\u003Cp>ii)&nbsp; Per Part 5 of ISO-10993, cytotoxicity testing standards require that the cytotoxicity be addressed at 24 hours and 48 hours, and that the results after 48 hours be less than or equal to Grade 2 by quantitative methods. The proposed responses and corrective actions incorrectly state the acceptance criteria to be, “Non cytotoxicity response with a test score of ≤2 at 24-Hour observation.”\u003C\u002Fp>\n\n\u003Cp>iii)&nbsp; The validation process and corrective actions fail to address the residual sterilant levels after the changed catheter wash procedure and device sterilization. Per ISO 10993-7, “A valid method of extraction and measurement shall be used to determine the amount of EO and, where necessary, ECH delivered to the patient.”\u003C\u002Fp>\n\n\u003Cp>iv)&nbsp; The proposed corrective actions do not address design transfer for the software validation functionality testing, in which there is failure to ensure that the device design is correctly translated into production specifications, as required by 21 CFR 820.30(h).\u003C\u002Fp>\n\n\u003Cp>b. It cannot be verified from the non-equipment software test report: coating tracker software \u003Cstrong>(b)(4)\u003C\u002Fstrong> that the tasks requiring a specific number of repeats for validation were conducted for the required number of repeats per the protocol.\u003C\u002Fp>\n\n\u003Cp>The responses dated June 16, 2022, July 18, 2022, and August 18, 2022 indicate that the root cause investigation is completed, additional review of all other previously completed non-equipment software production pertaining to the hydrophilic coating process were identified and are being implemented, and corrective actions are ongoing under CAPA\u003Cstrong>(b)(4)\u003C\u002Fstrong>. The adequacy of the responses cannot be determined until the outstanding inadequacies with CAPA\u003Cstrong>(b)(4)\u003C\u002Fstrong> under Observation 01 are addressed.\u003C\u002Fp>\n\n\u003Cp>2.&nbsp; Failure to establish and maintain adequate procedures for implementing and maintaining corrective and preventive actions, as required by 21 CFR 820.100. For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm’s Supplier Corrective Action Request (SCAR) Process \u003Cstrong>(b)(4)\u003C\u002Fstrong> requires that the firm open a SCAR “when it is determined that a supplier corrective action is need for an NCR” (Nonconformance Report). The FDA investigator collected examples of nonconformance reported quality problems where no SCAR was opened by your firm as required by its procedure. Additionally, because these corrective actions were taken as a result of these nonconformances outside of your firm’s corrective action procedures, no evaluation as to whether actions taken adversely affected the finished device was completed, nor were the corrections verified as effective, as required by 21 CFR 820.100(a)(4).\u003C\u002Fp>\n\n\u003Cp>The responses dated June 16, 2022, July 18, 2022, and August 18, 2022 are not adequate. Your firm initiated CAPA\u003Cstrong>(b)(4)\u003C\u002Fstrong> to address Observation 5 and identified five root causes. Your firm updated its procedure, \u003Cstrong>(b)(4)\u003C\u002Fstrong> to provide clarification to its employees as to when a SCAR needs to be initiated. Your firm submitted documentation that supports training of its employees on the new procedure. Your firm states that it will ensure each corrective and preventive action is effective through the Verification of Effectiveness process, though it is not clear exactly how and when that will occur. Your firm initiated a 3-year retrospective review of supplier NCR events where SCARs were not initiated and plans to evaluate any adverse effects of these NCRs as part of the CAPA underway. This activity is scheduled to be completed at the end of October 2022. The adequacy of your firm’s responses will be evaluated after you submit clarification of your plan to ensure effectiveness of the implemented corrective actions and documentation to support that effectiveness when complete.\u003C\u002Fp>\n\n\u003Cp>b. Your firm’s CAPA system fails to identify “rejects” as nonconforming product and therefore misses all nonconforming product during the manufacturing process as a quality data input for the CAPA system, as required by 21 CFR820.100(a)(1). Without nonconforming product as a quality data input to the CAPA system, the ability to detect recurring quality problems is greatly diminished.\u003C\u002Fp>\n\n\u003Cp>The responses dated June 16, 2022, July 18, 2022, and August 18, 2022 are not adequate. Your firm stated that its Quality Reporting procedure does require your firm to periodically review rejected material and that its employees “could” request a CAPA if they decided to based on that review. Your firm updated its CAPA procedure \u003Cstrong>(b)(4)\u003C\u002Fstrong> to include Reject data\u002Ftrend for consistent wording between its other relevant SOPs for Quality Reporting to be more clear that rejected material needs to be investigated as nonconforming product and that data needs to be fed into the CAPA system. Your firm stated that it has “made employees aware” and that effectiveness checks are planned to be completed by February 2023. It is not clear whether your firm has evaluated whether the periodic reviews of the rejected material historically have warranted an investigation. Information is needed to clarify whether a retrospective review has been completed or is planned.\u003C\u002Fp>\n\n\u003Cp>3.&nbsp; Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR 820.90(a). For example:\u003C\u002Fp>\n\n\u003Cp>During production and quality inspection, nonconforming product is identified as a “reject”. While rejected\u002Fnonconforming product is identified, documented, and segregated, the firm is not evaluating the nonconformance to determine the need for an investigation and notification of persons or organizations responsible for the nonconformance, as required by 21 CFR 820.90(a).\u003C\u002Fp>\n\n\u003Cp>The responses dated June 16, 2022, July 18, 2022, and August 18, 2022 are not adequate. Your firm made initial corrections to several procedures and definitions to ensure that rejected nonconforming product during the manufacturing process is accurately captured, trended, and fed into its CAPA system. Part of the issue related to a high reject rate was due to material that was destroyed during testing being labeled as “reject” in addition to actual nonconforming product. Your firm implemented an IT solution to label those samples separately as “destroyed” instead of “reject”. Your firm states that it has notified its relevant employees of the definition and procedure change. Your firm states that it plans to conduct effectiveness checks for CAPA \u003Cstrong>(b)(4)\u003C\u002Fstrong> and included the planned evaluation and timeframe for doing so, with a completion date of February 2023. Your firm also mentions a “preventive” action that plans to look at other product lines and systems where “reject” is used as a product designation to ensure that they are not missing any other nonconforming product documentation. It is not clear whether this includes a retrospective review of previous rejected materials in an attempt to determine whether an investigation needs to be opened into those nonconforming product. The adequacy of your firm’s responses will be evaluated after you provide information clarifying whether a retrospective review of rejected product will occur to determine whether an investigation can or should be done at this time.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration - CDRH\u002FORP\u002FDRP2\u003Cbr>\nCDRH Regulatory Inspections and Audit Team, WO66-1434\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Refer to CMS case # 472344 when replying\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the contents of this letter, please contact: Lydia Glaw, PhD at lydia.glaw@fda.hhs.gov or 301-796-1456.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Bram Zuckerman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Cardiovascular Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nAmy Smith\u003Cbr>\n35 Enterprise, Aliso Viejo, CA US 92656\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nCharlie Noel\n\nRecipient Title\n\nSVP, International Operations-CR\n\nMicroVention Costa Rica S.R.L.\n\nCoyol Free Zone, B 33 Zona Franca Coyol, Edificio B33\n\nEl Coyol De Alajuela, Alajuela\n\n20101\n\nCosta Rica\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nSeptember 30, 2022\n\nDear Charlie Noel:\n\nDuring an inspection of your firm located in Alajuela, Costa Rica, on May 23, 2022, through May 26, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Headway Microcatheter, LVIS, LVIS Jr, Scepter C and XC Occlusion Balloon Catheter, SOFIA Catheters, and BOBBY Balloon Guide Catheter. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received responses from Scafford Serron, Ph.D., VP of Global Quality dated June 16, 2022, July 18, 2022, and August 18, 2022, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations.\n\nThese violations include, but are not limited to, the following:\n\n1. Failure to verify a process that cannot be fully verified by subsequent inspection and test with a high degree of assurance and approved according to established procedures. The validation activities and results, including the date and signature of the individual(s) approving the validation and where appropriate the major equipment validated, shall be documented, as required by 21 CFR 820.75(a) – Process Validation. For example:\n\na. The catheter wash limitation process justifications (b)(4) dated October 31,2018 and (b)(4) dated June 10, 2021, do not specify the requirements for the catheter wash process validation prior to conducting the process validation. Additionally, the justifications provided for several test parameters do not provide a high degree of assurance and were not approved according to established procedures. Prior to the 2018 validation, this process had not been validated according to established procedures. Therefore, it is unknown if the catheter wash process sufficiently removes foreign material from the manufacturing process.\n\nThe responses dated June 16, 2022, July 18, 2022, and August 18, 2022 are not adequate. Your firm initiated CAPA(b)(4) to address Observation 1 and identified four root causes and training corrective actions, and conducted a retrospective review of processes requiring validation. Documents gathered at the inspection, “(b)(4)” (b)(4) and (b)(4), and provided in the response, “(b)(4)” (b)(4) require biocompatibility testing comply with ISO 10993-1. However, CAPA(b)(4) does not provide a high degree of assurance, as addressed in the FDA-recognized standard ISO-10993 [Biocompatibility]. For example:\n\ni) Per Part 1 of ISO-10993, a gap analysis and selection of biological endpoints for assessment is necessary to assess the biological safety of the medical device. The proposed responses and corrective actions do not address all biological endpoints, including pyrogenicity.\n\nii) Per Part 5 of ISO-10993, cytotoxicity testing standards require that the cytotoxicity be addressed at 24 hours and 48 hours, and that the results after 48 hours be less than or equal to Grade 2 by quantitative methods. The proposed responses and corrective actions incorrectly state the acceptance criteria to be, “Non cytotoxicity response with a test score of ≤2 at 24-Hour observation.”\n\niii) The validation process and corrective actions fail to address the residual sterilant levels after the changed catheter wash procedure and device sterilization. Per ISO 10993-7, “A valid method of extraction and measurement shall be used to determine the amount of EO and, where necessary, ECH delivered to the patient.”\n\niv) The proposed corrective actions do not address design transfer for the software validation functionality testing, in which there is failure to ensure that the device design is correctly translated into production specifications, as required by 21 CFR 820.30(h).\n\nb. It cannot be verified from the non-equipment software test report: coating tracker software (b)(4) that the tasks requiring a specific number of repeats for validation were conducted for the required number of repeats per the protocol.\n\nThe responses dated June 16, 2022, July 18, 2022, and August 18, 2022 indicate that the root cause investigation is completed, additional review of all other previously completed non-equipment software production pertaining to the hydrophilic coating process were identified and are being implemented, and corrective actions are ongoing under CAPA(b)(4). The adequacy of the responses cannot be determined until the outstanding inadequacies with CAPA(b)(4) under Observation 01 are addressed.\n\n2. Failure to establish and maintain adequate procedures for implementing and maintaining corrective and preventive actions, as required by 21 CFR 820.100. For example:\n\na. Your firm’s Supplier Corrective Action Request (SCAR) Process (b)(4) requires that the firm open a SCAR “when it is determined that a supplier corrective action is need for an NCR” (Nonconformance Report). The FDA investigator collected examples of nonconformance reported quality problems where no SCAR was opened by your firm as required by its procedure. Additionally, because these corrective actions were taken as a result of these nonconformances outside of your firm’s corrective action procedures, no evaluation as to whether actions taken adversely affected the finished device was completed, nor were the corrections verified as effective, as required by 21 CFR 820.100(a)(4).\n\nThe responses dated June 16, 2022, July 18, 2022, and August 18, 2022 are not adequate. Your firm initiated CAPA(b)(4) to address Observation 5 and identified five root causes. Your firm updated its procedure, (b)(4) to provide clarification to its employees as to when a SCAR needs to be initiated. Your firm submitted documentation that supports training of its employees on the new procedure. Your firm states that it will ensure each corrective and preventive action is effective through the Verification of Effectiveness process, though it is not clear exactly how and when that will occur. Your firm initiated a 3-year retrospective review of supplier NCR events where SCARs were not initiated and plans to evaluate any adverse effects of these NCRs as part of the CAPA underway. This activity is scheduled to be completed at the end of October 2022. The adequacy of your firm’s responses will be evaluated after you submit clarification of your plan to ensure effectiveness of the implemented corrective actions and documentation to support that effectiveness when complete.\n\nb. Your firm’s CAPA system fails to identify “rejects” as nonconforming product and therefore misses all nonconforming product during the manufacturing process as a quality data input for the CAPA system, as required by 21 CFR820.100(a)(1). Without nonconforming product as a quality data input to the CAPA system, the ability to detect recurring quality problems is greatly diminished.\n\nThe responses dated June 16, 2022, July 18, 2022, and August 18, 2022 are not adequate. Your firm stated that its Quality Reporting procedure does require your firm to periodically review rejected material and that its employees “could” request a CAPA if they decided to based on that review. Your firm updated its CAPA procedure (b)(4) to include Reject data\u002Ftrend for consistent wording between its other relevant SOPs for Quality Reporting to be more clear that rejected material needs to be investigated as nonconforming product and that data needs to be fed into the CAPA system. Your firm stated that it has “made employees aware” and that effectiveness checks are planned to be completed by February 2023. It is not clear whether your firm has evaluated whether the periodic reviews of the rejected material historically have warranted an investigation. Information is needed to clarify whether a retrospective review has been completed or is planned.\n\n3. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR 820.90(a). For example:\n\nDuring production and quality inspection, nonconforming product is identified as a “reject”. While rejected\u002Fnonconforming product is identified, documented, and segregated, the firm is not evaluating the nonconformance to determine the need for an investigation and notification of persons or organizations responsible for the nonconformance, as required by 21 CFR 820.90(a).\n\nThe responses dated June 16, 2022, July 18, 2022, and August 18, 2022 are not adequate. Your firm made initial corrections to several procedures and definitions to ensure that rejected nonconforming product during the manufacturing process is accurately captured, trended, and fed into its CAPA system. Part of the issue related to a high reject rate was due to material that was destroyed during testing being labeled as “reject” in addition to actual nonconforming product. Your firm implemented an IT solution to label those samples separately as “destroyed” instead of “reject”. Your firm states that it has notified its relevant employees of the definition and procedure change. Your firm states that it plans to conduct effectiveness checks for CAPA (b)(4) and included the planned evaluation and timeframe for doing so, with a completion date of February 2023. Your firm also mentions a “preventive” action that plans to look at other product lines and systems where “reject” is used as a product designation to ensure that they are not missing any other nonconforming product documentation. It is not clear whether this includes a retrospective review of previous rejected materials in an attempt to determine whether an investigation needs to be opened into those nonconforming product. The adequacy of your firm’s responses will be evaluated after you provide information clarifying whether a retrospective review of rejected product will occur to determine whether an investigation can or should be done at this time.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\n\nFood and Drug Administration - CDRH\u002FORP\u002FDRP2\n\nCDRH Regulatory Inspections and Audit Team, WO66-1434\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to CMS case # 472344 when replying.\n\nIf you have any questions about the contents of this letter, please contact: Lydia Glaw, PhD at lydia.glaw@fda.hhs.gov or 301-796-1456.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBram Zuckerman, M.D.\n\nDirector\n\nOffice of Cardiovascular Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nAmy Smith\n\n35 Enterprise, Aliso Viejo, CA US 92656","MicroVention Costa Rica S.R.L.","microvention-costa-rica-srl-643188-09302022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrovention-costa-rica-srl-643188-09302022","2026-10-26T08:09:24.922135+00:00","Closed Out","2023-02-07","643188","2025-11-17","Charlie Noel","2026-08-20T01:16:19.813+00:00","2022-09-30",{"id":157,"raw":158,"subject":162,"body_html":163,"body_text":164,"firm_name":165,"letter_id":166,"created_at":106,"fei_number":19,"letter_url":167,"updated_at":168,"action_type":22,"case_status":23,"posted_date":169,"marcs_cms_no":170,"product_type":47,"closeout_date":19,"issuing_office":37,"recipient_name":171,"body_fetched_at":172,"delivery_method":50,"recipient_title":19,"reference_number":173,"action_taken_date":174,"medical_device_id":19,"response_letter_date":19},248,[159,160,161,37,162,13,13,13],"\u003Ctime datetime=\"2026-03-31T04:00:00Z\">03\u002F31\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-16T04:00:00Z\">03\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrobiological-testing-consulting-llc-720374-03162026\">Microbiological Testing &amp; Consulting, LLC\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-53\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Lauren Szarzynski\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Microbiological Testing &amp; Consulting, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5661 W. 120th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alsip\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60803\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:lauren@mtcresearch.com\"> lauren@mtcresearch.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-53\u003C\u002Fp>\u003Cp>March 16, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Szarzynski:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your contract testing laboratory, Microbiological Testing &amp; Consulting, LLC, FEI 3003875820, at 5661 W. 120th Street, Alsip, from September 8 to 16, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, the drug products you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your September 30, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.160(b) and 21 CFR 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm is a contract testing laboratory that conducts testing of various application and nonapplication drug products for your customers. You failed to conduct appropriate testing to ensure that the results your firm provided to customers were accurate and scientifically sound.\u003C\u002Fp>\u003Cp>\u003Cem>Lack of Adequate Documentation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm lacks significant CGMP documentation for your microbiological testing. For example, you routinely failed to document specific attributes of each test such as:\u003C\u002Fp>\u003Cul>\u003Cli>equipment number\u003C\u002Fli>\u003Cli>sample size\u003C\u002Fli>\u003Cli>media batch number\u003C\u002Fli>\u003Cli>sample dilutions\u003C\u002Fli>\u003Cli>incubation temperatures\u003C\u002Fli>\u003Cli>name\u002Fsignature of performing analyst\u003C\u002Fli>\u003C\u002Ful>\u003Cp>According to your personnel, your firm also lacked adequate equipment logs to track usage and maintenance.\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to performing a comprehensive review of your testing operations and records. Based on the outcome of the review, your firm plans to update the affected data and test forms. You did not provide specific details on the records, equipment, and data that will be evaluated, nor did you commit to conducting a full retrospective review of test results provided to your customers.\u003C\u002Fp>\u003Cp>Additionally, you indicate that going forward you will meet standards for laboratory studies. Please note that appropriate regulatory requirements for laboratories conducting testing for drug product manufacturers are 21 CFR parts 210 and 211 and Section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Laboratory investigations cannot be performed when systems, procedures, and documentation are deficient.\u003C\u002Fp>\u003Cp>Complete and accurate records are necessary to ensure that test methods are consistently followed and reproducible. Additionally, complete test records are necessary to reliably conduct record reviews and adequately investigate deviations and drug product failures.\u003C\u002Fp>\u003Cp>\u003Cem>Lack of Appropriate Media Qualification\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You lack adequate controls to ensure the reliability of your microbiological testing results. For example, the media used to test your customers drug products was inadequately qualified. You lacked screening for inhibitory properties of your incoming lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your response, you commit to reviewing your tests and methods to identify gaps and implement the appropriate remediation.\u003C\u002Fp>\u003Cp>Your response is inadequate because you did not commit to pausing testing until assessments are complete, nor did you implement any interim corrective actions. Furthermore, your firm did not provide a plan to re-assess results that have been communicated to customers.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, test results, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A retrospective risk assessment of gaps found in your growth media qualification and suitability testing practices over the past three years. Describe how these gaps will be remediated to ensure reliable microbial enumeration and appropriate identification of objectionable microorganisms.\u003C\u002Fli>\u003Cli>A complete assessment of documentation systems used throughout your laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm lacks appropriate systems and procedures for quality oversight of laboratory testing, documentation, and investigations.\u003C\u002Fp>\u003Cp>As noted in the prior charge, your quality unit did not have adequate oversight of documentation, media qualification, and other critical microbiology laboratory programs. In addition, you lacked adequate systems for investigations and ensuring analyst competencies.\u003C\u002Fp>\u003Cp>Furthermore, your management stated that in the past two years your firm conducted only one product out-of-specification (OOS) investigation and one water out-of-limit (OOL) for total aerobic microbial count (TAMC) investigation. These two investigations were the only ones available for our investigator to review. However, records collected during an FDA inspection of one of your customers \u003Cstrong>(b)(4)\u003C\u002Fstrong>, indicated that your firm reported several OOL for TAMC and objectionable microorganism results within the past two years. It appears that your firm did not make all requested OOS\u002FOOL test data available during the inspection.\u003C\u002Fp>\u003Cp>In your response, you commit to implement a multiphase OOS investigation methodology. Your response is inadequate. You did not commit to assessing previous OOS results to ensure the investigations were adequate.\u003C\u002Fp>\u003Cp>Be reminded that it is your responsibility to ensure all data and information provided are accurate, complete, and readily available for inspection. As a contract laboratory, you must comply with the CGMP regulations that apply to operations you perform, including, but not limited to, those that address the operations of your quality control unit, laboratory, investigation system, and documentation system.\u003C\u002Fp>\u003Cp>\u003Cem>Training Program\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your training program is inadequate. CGMP training is not regularly performed at your firm as required by your established procedure. During the inspection, you could not provide records of CGMP training.\u003C\u002Fp>\u003Cp>In your response, you state a consultant will assess your training procedure for general CGMP requirements and a suitable CGMP training program shall be developed.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide any immediate steps to address the training program to ensure all employees are adequately trained to complete CGMP activities. Nor do you commit to stop testing until employees can receive appropriate CGMP training.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective, independent review of all invalidated OOL\u002FOOS (including raw material, in-process, and release\u002Fstability testing) results for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOL\u002FOOS:\u003Cbr>o Provide a list of all OOS and OOL results that were not investigated and your corresponding corrective actions including a reassessment of all instances to determine any additional action needed related to nonconforming results.\u003Cbr>o For each OOL\u002FOOS include your CAPA and how you will ensure all OOS and OOL results will be investigated and communicated in a timely manner to your customer(s) on the certificate of analysis for appropriate follow up.\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated OOL\u002FOOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o An explanation for the discrepancy in the number of OOL and objectionable microorganism investigations that you provided to our investigator compared with the number that you provided to your customer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOL\u002FOOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003Cbr>o Quality unit oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Adequate scoping of each investigation and its CAPA\u003Cbr>o Assurance that data, findings, and supporting documentation relating to any OOS\u002FOOL result are promptly conveyed to customers\u003Cbr>o Revised OOL\u002FOOS investigation procedures with these and other remediations\u003C\u002Fli>\u003Cli>A description of how top management supports quality assurance and reliable test operations including, but not limited to, timely provision of resources to proactively address emerging quality issues and to assure a continuing state of control.\u003C\u002Fli>\u003Cli>Documentation of training for all relevant personnel on revised policies, procedures, and other associated items.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003Cbr>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Responsibilities of Contract Testing Lab\u003C\u002Fstrong>\u003Cbr>FDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your customers. It is essential that you understand your responsibility to operate in full compliance with CGMP, and that you inform all your customers of any OOS results or significant problems encountered during the testing of these drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm; you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003875820 and ATTN: Marva Taylor.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>______________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-26-53\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Lauren Szarzynski\n\nRecipient Title\n\nOwner\n\nMicrobiological Testing & Consulting, LLC\n\n5661 W. 120th Street\n\nAlsip, IL 60803\n\nUnited States\n\nlauren@mtcresearch.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-53\nMarch 16, 2026\nDear Ms. Szarzynski:\nThe United States Food and Drug Administration (FDA) inspected your contract testing laboratory, Microbiological Testing & Consulting, LLC, FEI 3003875820, at 5661 W. 120th Street, Alsip, from September 8 to 16, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, the drug products you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your September 30, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.160(b) and 21 CFR 211.165(b)).\nYour firm is a contract testing laboratory that conducts testing of various application and nonapplication drug products for your customers. You failed to conduct appropriate testing to ensure that the results your firm provided to customers were accurate and scientifically sound.\nLack of Adequate Documentation\nYour firm lacks significant CGMP documentation for your microbiological testing. For example, you routinely failed to document specific attributes of each test such as:\nequipment number\nsample size\nmedia batch number\nsample dilutions\nincubation temperatures\nname\u002Fsignature of performing analyst\nAccording to your personnel, your firm also lacked adequate equipment logs to track usage and maintenance.\nYour response is inadequate. You commit to performing a comprehensive review of your testing operations and records. Based on the outcome of the review, your firm plans to update the affected data and test forms. You did not provide specific details on the records, equipment, and data that will be evaluated, nor did you commit to conducting a full retrospective review of test results provided to your customers.\nAdditionally, you indicate that going forward you will meet standards for laboratory studies. Please note that appropriate regulatory requirements for laboratories conducting testing for drug product manufacturers are 21 CFR parts 210 and 211 and Section 501(a)(2)(B) of the FD&C Act.\nLaboratory investigations cannot be performed when systems, procedures, and documentation are deficient.\nComplete and accurate records are necessary to ensure that test methods are consistently followed and reproducible. Additionally, complete test records are necessary to reliably conduct record reviews and adequately investigate deviations and drug product failures.\nLack of Appropriate Media Qualification\nYou lack adequate controls to ensure the reliability of your microbiological testing results. For example, the media used to test your customers drug products was inadequately qualified. You lacked screening for inhibitory properties of your incoming lots of (b)(4).\nIn your response, you commit to reviewing your tests and methods to identify gaps and implement the appropriate remediation.\nYour response is inadequate because you did not commit to pausing testing until assessments are complete, nor did you implement any interim corrective actions. Furthermore, your firm did not provide a plan to re-assess results that have been communicated to customers.\nIn response to this letter, provide:\nA comprehensive independent assessment of your laboratory practices, procedures, methods, test results, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA retrospective risk assessment of gaps found in your growth media qualification and suitability testing practices over the past three years. Describe how these gaps will be remediated to ensure reliable microbial enumeration and appropriate identification of objectionable microorganisms.\nA complete assessment of documentation systems used throughout your laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour firm lacks appropriate systems and procedures for quality oversight of laboratory testing, documentation, and investigations.\nAs noted in the prior charge, your quality unit did not have adequate oversight of documentation, media qualification, and other critical microbiology laboratory programs. In addition, you lacked adequate systems for investigations and ensuring analyst competencies.\nFurthermore, your management stated that in the past two years your firm conducted only one product out-of-specification (OOS) investigation and one water out-of-limit (OOL) for total aerobic microbial count (TAMC) investigation. These two investigations were the only ones available for our investigator to review. However, records collected during an FDA inspection of one of your customers (b)(4), indicated that your firm reported several OOL for TAMC and objectionable microorganism results within the past two years. It appears that your firm did not make all requested OOS\u002FOOL test data available during the inspection.\nIn your response, you commit to implement a multiphase OOS investigation methodology. Your response is inadequate. You did not commit to assessing previous OOS results to ensure the investigations were adequate.\nBe reminded that it is your responsibility to ensure all data and information provided are accurate, complete, and readily available for inspection. As a contract laboratory, you must comply with the CGMP regulations that apply to operations you perform, including, but not limited to, those that address the operations of your quality control unit, laboratory, investigation system, and documentation system.\nTraining Program\nYour training program is inadequate. CGMP training is not regularly performed at your firm as required by your established procedure. During the inspection, you could not provide records of CGMP training.\nIn your response, you state a consultant will assess your training procedure for general CGMP requirements and a suitable CGMP training program shall be developed.\nYour response is inadequate. You do not provide any immediate steps to address the training program to ensure all employees are adequately trained to complete CGMP activities. Nor do you commit to stop testing until employees can receive appropriate CGMP training.\nIn response to this letter, provide:\nA retrospective, independent review of all invalidated OOL\u002FOOS (including raw material, in-process, and release\u002Fstability testing) results for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOL\u002FOOS:\no Provide a list of all OOS and OOL results that were not investigated and your corresponding corrective actions including a reassessment of all instances to determine any additional action needed related to nonconforming results.\no For each OOL\u002FOOS include your CAPA and how you will ensure all OOS and OOL results will be investigated and communicated in a timely manner to your customer(s) on the certificate of analysis for appropriate follow up.\no Determine whether the scientific justification and evidence relating to the invalidated OOL\u002FOOS result conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no An explanation for the discrepancy in the number of OOL and objectionable microorganism investigations that you provided to our investigator compared with the number that you provided to your customer, (b)(4).\nA comprehensive review and remediation plan for your OOL\u002FOOS result investigation systems. The CAPA should include but not be limited to addressing the following:\no Quality unit oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Adequate scoping of each investigation and its CAPA\no Assurance that data, findings, and supporting documentation relating to any OOS\u002FOOL result are promptly conveyed to customers\no Revised OOL\u002FOOS investigation procedures with these and other remediations\nA description of how top management supports quality assurance and reliable test operations including, but not limited to, timely provision of resources to proactively address emerging quality issues and to assure a continuing state of control.\nDocumentation of training for all relevant personnel on revised policies, procedures, and other associated items.\nData Integrity Remediation\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\nResponsibilities of Contract Testing Lab\nFDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your customers. It is essential that you understand your responsibility to operate in full compliance with CGMP, and that you inform all your customers of any OOS results or significant problems encountered during the testing of these drugs.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm; you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003875820 and ATTN: Marva Taylor.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n______________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Microbiological Testing & Consulting, LLC","microbiological-testing-consulting-llc-720374-03162026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrobiological-testing-consulting-llc-720374-03162026","2026-10-26T08:09:24.793253+00:00","2026-03-31","720374","Ms. Lauren Szarzynski","2026-08-19T04:49:49.638+00:00","320-26-53","2026-03-16",{"id":176,"raw":177,"subject":12,"body_html":182,"body_text":183,"firm_name":184,"letter_id":185,"created_at":186,"fei_number":19,"letter_url":187,"updated_at":188,"action_type":22,"case_status":149,"posted_date":189,"marcs_cms_no":190,"product_type":26,"closeout_date":191,"issuing_office":11,"recipient_name":192,"body_fetched_at":193,"delivery_method":194,"recipient_title":19,"reference_number":19,"action_taken_date":195,"medical_device_id":19,"response_letter_date":19},2802,[178,179,180,11,12,13,181,13],"\u003Ctime datetime=\"2022-03-22T13:20:00Z\">03\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-01-06T05:00:00Z\">01\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funimicro-medical-systems-shenzhen-co-ltd-624560-01062022\">Unimicro Medical Systems-Shenzhen Co., Ltd.\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funimicro-medical-systems-shenzhen-co-ltd-624560-05182023\">\u003Ctime datetime=\"2023-05-31T04:00:00Z\">05\u002F31\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Roly Lee\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Unimicro Medical Systems-Shenzhen Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>201, Bldg 38 101 Heshui Kou\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gongmingzhen Longgang\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shenzhen\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>518106\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 6, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Roly Lee:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Shenzhen, China, on September 15, 2021, through September 26, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Veress Pneumoperitoneum Needles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements as required by 21 CFR 820.90(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm has not established a disposition process for product that does not conform to specified requirements. Your firm was not able to provide the disposition of \u003Cstrong>(b)(4)\u003C\u002Fstrong> package heat sealed nonconforming products. In Nonconforming Product Handling Sheet (No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>), your firm noted \u003Cstrong>(b)(4)\u003C\u002Fstrong> package heat sealing nonconformances. For these \u003Cstrong>(b)(4)\u003C\u002Fstrong> nonconforming products, the final determination was stated as “return to warehouse” and no final disposition was provided or conducted, per Nonconforming Product Control Procedure (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Therefore, it is unknown where these products are or how they were handled. Additionally, your firm’s staff was unaware of the nonconforming product procedure or handling and disposition of nonconforming products.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to stop any products exporting to the United States of America until corrective actions are completed and deactivate all products from your Device Listings until the corrective actions are completed. You also plan to modify the Nonconforming Product Control Procedure, train relevant personnel of the design, purchasing, quality, production, warehouse, logistics, and sales department according to the revised procedure. You state you will also perform retrospective review for all products which have been sold for the US market, to analyze if there is any quality issue or adverse events that have occurred. However, to ensure a sufficient evaluation of the risk posed by the situation, you should also actively evaluate the risks associated with the device presently and take any needed actions to mitigate those risks. This should not rely only on adverse event reporting or other outside reporting. Additionally, your Corrective Action Plan does not include ensuring the disposition of nonconforming products are documented. As part of your corrective actions, you should document the disposition of the identified nonconforming products.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met as required by 21 CFR 820.30(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm was unable to provide documentation and\u002For evidence of conducting Design and Development activities as described in the Design and Development Control Procedures (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>), related to the veress pneumoperitoneum needles. In this document, the procedures for design control are described in detail. The procedures include steps to review the design input, output, verification and validation, design changes, design transfer, and design history. However, your firm was unable to provide documentation and data demonstrating design requirements for the veress pneumoperitoneum needles wet met, as required by the Design and Development Control Procedures.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to modify the Design and Development Control Procedure based on the requirements of 21 CFR 820.30 Design Control, train all design personnel according to the revised procedure, and to retrospectively review all products which have been sold for the U.S market, to analyze if there is any quality issue or adverse events occurred. However, you have no plan to evaluate the retrospectively conduct design control activities for affected products. You should conduct a review of your products to determine which products did not have design control activities conducted and retrospectively conduct those activities to ensure products meet design requirements. In addition, you should actively assess if lack of design control activities could have led to the distribution of nonconforming products (aside from review of adverse event or malfunction reports). If any risks are identified, you should take appropriate action to mitigate those risks.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm was unable to provide validation documentation with objective evidence and data for activities related to the manufacturing of medical devices, specifically EtO Sterilization, Heat Sealing Packaging, and UV Glue Curing documented in the Validation Management Control Procedure (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. No. \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>), Sealing Machine Sealing Effect Re-Verification Program (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>), Sealing Machine Sealing Effect Re-Verification Report (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>), UV Curing Re-Verification Program (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Your firm also did not have personnel familiar with process validation.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to modify the validation management control procedure based on the requirement of 21 CFR 820.75 Process validation, train all validation personnel according to the revised procedure, re-validate all other special processes identified for U.S products such as the ultrasonic cleaning process and ultrasonic welding process, and re-validate the EtO sterilization process, heat sealing packaging process, and UV glue curing process. However, these activities have not been completed. In addition, you have not indicated if or how you plan to assess any potential impacts of the lack of process validation on previously distributed product and how you plan to mitigate any associated risks. To ensure safety and conformity of product, it is important that you assess the potential impact the lack of process validation as described above, may have had on previously distributed products as part of your corrective action plan.\u003C\u002Fp>\n\n\u003Cp>4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action as required by 21 CFR 820.100(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm did not provide a severity determination, or a root cause analysis conducted for CAPA events deemed “necessary”. The CAPA states a root cause analysis is required to be conducted only if necessary. However, your firm has not defined what CAPA events are necessary in the Corrective and Preventive Actions Control Procedure (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong> Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong> dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>). In the document, your firm utilizes an in-process CAPA, which requires a severity determination, which is not defined in the procedure. There is no documented definition, requirement, or guidance in the procedure for the severity determination. Also, no root cause analysis was performed in your firm’s two most recent CAPAs, (Abnormal Manufacturing Process Feedback Memo \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Model MND11500 and Model MND11200).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to modify the Corrective and Preventive Action Control Procedure to define severity (Major, Moderate, or Minor), and define what is “necessary” when requiring a root cause analysis. You intend to train relevant personnel of all departments according to the revised procedure. You also state you will investigate the past CAPAs and customer complaints, to confirm whether there is any improper handling of CAPAs or customer complaints, and to evaluate the risks to the products that have been sold in the US market. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\u003C\u002Fp>\n\n\u003Cp>5. Failure to adequately establish and maintain procedures to ensure that equipment is routinely calibrated, inspected, checked, and maintained as required by 21 CFR 820.72(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm was not able to provide calibration documentation and data related to equipment and instruments including leakage tester and push &amp; pull tester, used in the manufacturing of medical devices intended for the US market. Your firm was able to provide the calibration procedure, Production Equipment Management Control Procedure (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>). However, when calibration documentation for equipment and instruments used during the manufacturing of the Class II Veress Needles, such as their Leakage Tester and Push &amp; Pull Tester, your firm was unable to provide calibration documentation and data.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to modify the production equipment management control procedure based on the requirements of 21 CFR 820.72(a) and train relevant personnel of quality, production, and warehouse departments according to the revised procedure. You also plan to send Leakage Tester and Push&amp;Pull Tester to the Calibration institute for calibration. Additionally, you state that you will review the impact of their Leakage Tester and Push&amp;Pull Tester on the product test results during the failure period based on the calibration results. Lastly, you plan to review the measuring and test equipment for any of the same issues for other inspection, measuring, and test equipment. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed, and documentation verifying the successful completion of these actions are provided.\u003C\u002Fp>\n\n\u003Cp>6. Failure to adequately establish and maintain acceptance procedures, where appropriate, to ensure that specified requirements for in-process product are met as required by 21 CFR 820.80(c).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm’s Veress Needle Quality Inspection Standard (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>) is not adequately established, as the quality control personnel were conducting in-process acceptance activities that did not include connection bond testing, and puncture testing of the subject device. Your firm has not established and maintained in-process acceptance activity procedures to ensure specified requirements for in-process products are met. The quality personnel were conducting acceptance activities based on the Inspection Standard used to conduct in-process acceptance activities for the Veress Needles. However, according to the investigator, your firm’s quality staff conducting the in-process acceptance activities were not familiar with the testing process and stated there were no established in-process acceptance procedures for the connection bond and puncture testing. However, in the Semi-Finished Inspection Record (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), there is a requirement included to conduct a connection bond test and puncture test, that the quality staff conducting the in-process acceptance activities were not familiar with. The requirement listed in the semi-finished inspection record was not included in the final Veress Needle Quality Inspection Standard.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021, and have concluded it is not adequate. You plan to modify the Veress Needle Quality Inspection Standard and all other quality inspection standards, train relevant personnel of the quality and production department according to the revised Quality Inspection Standards, and perform retrospective review for all products which had been sold for the U.S market, to analyze if there is any quality issue or adverse event occurred. These actions have not been completed. In addition, your firm has not identified plans to evaluate their document control system, to make changes to ensure the requirements are consistent across documents. To ensure conformance to the standard across all relevant in-process acceptance activities, you should evaluate your document control system as part of your corrective action plan.\u003C\u002Fp>\n\n\u003Cp>7. Failure to adequately establish and maintain procedures to ensure that DHR's for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR, and the requirements of this part as required by 21 CFR 820.184\u003C\u002Fp>\n\n\u003Cp>For example: Your firm was not able to provide Device History Records for their manufactured medical devices intended and exported to the US market. Your firm was unfamiliar with FDA regulations and requirements for manufactures to include the DHR requirements and their Device History Record Control Procedures (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You state you intend to modify their DHR control procedures based on the requirements of 21 CFR 820.184 and perform sample inspection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of the subject device based on the revised procedure, to confirm the integrity and correctness of the DHRs. You also plan to train relevant personnel on design, purchasing, quality, production, warehouse, logistics, PMC, and sales department according to the revised procedures and your firm plans to perform a retrospective review for all products which had been sold for the US market. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\u003C\u002Fp>\n\n\u003Cp>8. Failure to maintain device master records (DMRs) as required by 21 CFR 820.181.\u003C\u002Fp>\n\n\u003Cp>For example: Your firm has not maintained their Device Master Records related to the subject device, and the personnel was unfamiliar with documents, processes, and medical devices related to the U.S market. Additionally, the manager of the site was not familiar with the FDA regulatory requirements to include DMRs for medical device manufacturers.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to output DMRs according to the reorganized Device History File for all products exported and intended for the U.S market, and to retrospectively review for all products which have been sold for the US market, to analyze if there are any quality issues or adverse events that have occurred. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\u003C\u002Fp>\n\n\u003Cp>Given the serious nature of the violations of the Act, Veress Pneumoperitoneum Needles manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as 'detention without physical examination,' until these violations are corrected. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and correct the violations described in this letter. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response. Please provide a translation of documentation not in English to facilitate our review.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration - CDRH\u002FORP\u002FDRP2\u003Cbr>\nCDRH Regulatory Inspections and Audit Team, WO66-1434\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Refer to CMS case #424228 when replying\u003C\u002Fstrong>. If you have any questions about the contents of this letter, please contact: OHT Assistant Director, Jason Roberts at jason.roberts@fda.hhs.gov or (240)402-6400\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely Yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nOffice Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nZeyu Chen\u003Cbr>\n238 Fernwood Ave, Edison, NEW JERSEY 08837\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRoly Lee\n\nRecipient Title\n\nGeneral Manager\n\nUnimicro Medical Systems-Shenzhen Co., Ltd.\n\n201, Bldg 38 101 Heshui Kou\n\nGongmingzhen Longgang\n\nShenzhen\n\n518106\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nJanuary 6, 2022\n\nDear Roly Lee:\n\nDuring an inspection of your firm located in Shenzhen, China, on September 15, 2021, through September 26, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Veress Pneumoperitoneum Needles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements as required by 21 CFR 820.90(a).\n\nFor example: Your firm has not established a disposition process for product that does not conform to specified requirements. Your firm was not able to provide the disposition of (b)(4) package heat sealed nonconforming products. In Nonconforming Product Handling Sheet (No. (b)(4), dated (b)(4)), your firm noted (b)(4) package heat sealing nonconformances. For these (b)(4) nonconforming products, the final determination was stated as “return to warehouse” and no final disposition was provided or conducted, per Nonconforming Product Control Procedure (Doc No. (b)(4), Ver. (b)(4), and dated (b)(4)). Therefore, it is unknown where these products are or how they were handled. Additionally, your firm’s staff was unaware of the nonconforming product procedure or handling and disposition of nonconforming products.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to stop any products exporting to the United States of America until corrective actions are completed and deactivate all products from your Device Listings until the corrective actions are completed. You also plan to modify the Nonconforming Product Control Procedure, train relevant personnel of the design, purchasing, quality, production, warehouse, logistics, and sales department according to the revised procedure. You state you will also perform retrospective review for all products which have been sold for the US market, to analyze if there is any quality issue or adverse events that have occurred. However, to ensure a sufficient evaluation of the risk posed by the situation, you should also actively evaluate the risks associated with the device presently and take any needed actions to mitigate those risks. This should not rely only on adverse event reporting or other outside reporting. Additionally, your Corrective Action Plan does not include ensuring the disposition of nonconforming products are documented. As part of your corrective actions, you should document the disposition of the identified nonconforming products.\n\n2. Failure to adequately establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met as required by 21 CFR 820.30(a).\n\nFor example: Your firm was unable to provide documentation and\u002For evidence of conducting Design and Development activities as described in the Design and Development Control Procedures (Doc No. (b)(4), Ver. (b)(4), dated (b)(4)), related to the veress pneumoperitoneum needles. In this document, the procedures for design control are described in detail. The procedures include steps to review the design input, output, verification and validation, design changes, design transfer, and design history. However, your firm was unable to provide documentation and data demonstrating design requirements for the veress pneumoperitoneum needles wet met, as required by the Design and Development Control Procedures.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to modify the Design and Development Control Procedure based on the requirements of 21 CFR 820.30 Design Control, train all design personnel according to the revised procedure, and to retrospectively review all products which have been sold for the U.S market, to analyze if there is any quality issue or adverse events occurred. However, you have no plan to evaluate the retrospectively conduct design control activities for affected products. You should conduct a review of your products to determine which products did not have design control activities conducted and retrospectively conduct those activities to ensure products meet design requirements. In addition, you should actively assess if lack of design control activities could have led to the distribution of nonconforming products (aside from review of adverse event or malfunction reports). If any risks are identified, you should take appropriate action to mitigate those risks.\n\n3. Failure to adequately establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b).\n\nFor example: Your firm was unable to provide validation documentation with objective evidence and data for activities related to the manufacturing of medical devices, specifically EtO Sterilization, Heat Sealing Packaging, and UV Glue Curing documented in the Validation Management Control Procedure (Doc No. (b)(4), Ver. No. (b)(4) and dated (b)(4)), Sealing Machine Sealing Effect Re-Verification Program (Doc No. (b)(4), Ver. (b)(4) and dated (b)(4)), Sealing Machine Sealing Effect Re-Verification Report (Doc No. (b)(4), Ver. (b)(4) and dated (b)(4)), UV Curing Re-Verification Program (Doc No. (b)(4), Ver. (b)(4) and dated (b)(4)). Your firm also did not have personnel familiar with process validation.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to modify the validation management control procedure based on the requirement of 21 CFR 820.75 Process validation, train all validation personnel according to the revised procedure, re-validate all other special processes identified for U.S products such as the ultrasonic cleaning process and ultrasonic welding process, and re-validate the EtO sterilization process, heat sealing packaging process, and UV glue curing process. However, these activities have not been completed. In addition, you have not indicated if or how you plan to assess any potential impacts of the lack of process validation on previously distributed product and how you plan to mitigate any associated risks. To ensure safety and conformity of product, it is important that you assess the potential impact the lack of process validation as described above, may have had on previously distributed products as part of your corrective action plan.\n\n4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action as required by 21 CFR 820.100(a).\n\nFor example: Your firm did not provide a severity determination, or a root cause analysis conducted for CAPA events deemed “necessary”. The CAPA states a root cause analysis is required to be conducted only if necessary. However, your firm has not defined what CAPA events are necessary in the Corrective and Preventive Actions Control Procedure (Doc No. (b)(4) Ver. (b)(4) dated (b)(4)). In the document, your firm utilizes an in-process CAPA, which requires a severity determination, which is not defined in the procedure. There is no documented definition, requirement, or guidance in the procedure for the severity determination. Also, no root cause analysis was performed in your firm’s two most recent CAPAs, (Abnormal Manufacturing Process Feedback Memo (b)(4) for Model MND11500 and Model MND11200).\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to modify the Corrective and Preventive Action Control Procedure to define severity (Major, Moderate, or Minor), and define what is “necessary” when requiring a root cause analysis. You intend to train relevant personnel of all departments according to the revised procedure. You also state you will investigate the past CAPAs and customer complaints, to confirm whether there is any improper handling of CAPAs or customer complaints, and to evaluate the risks to the products that have been sold in the US market. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\n\n5. Failure to adequately establish and maintain procedures to ensure that equipment is routinely calibrated, inspected, checked, and maintained as required by 21 CFR 820.72(a).\n\nFor example: Your firm was not able to provide calibration documentation and data related to equipment and instruments including leakage tester and push & pull tester, used in the manufacturing of medical devices intended for the US market. Your firm was able to provide the calibration procedure, Production Equipment Management Control Procedure (Doc No. (b)(4), Ver. (b)(4), and dated (b)(4)). However, when calibration documentation for equipment and instruments used during the manufacturing of the Class II Veress Needles, such as their Leakage Tester and Push & Pull Tester, your firm was unable to provide calibration documentation and data.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to modify the production equipment management control procedure based on the requirements of 21 CFR 820.72(a) and train relevant personnel of quality, production, and warehouse departments according to the revised procedure. You also plan to send Leakage Tester and Push&Pull Tester to the Calibration institute for calibration. Additionally, you state that you will review the impact of their Leakage Tester and Push&Pull Tester on the product test results during the failure period based on the calibration results. Lastly, you plan to review the measuring and test equipment for any of the same issues for other inspection, measuring, and test equipment. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed, and documentation verifying the successful completion of these actions are provided.\n\n6. Failure to adequately establish and maintain acceptance procedures, where appropriate, to ensure that specified requirements for in-process product are met as required by 21 CFR 820.80(c).\n\nFor example: Your firm’s Veress Needle Quality Inspection Standard (Doc No. (b)(4), Ver. (b)(4), dated (b)(4)) is not adequately established, as the quality control personnel were conducting in-process acceptance activities that did not include connection bond testing, and puncture testing of the subject device. Your firm has not established and maintained in-process acceptance activity procedures to ensure specified requirements for in-process products are met. The quality personnel were conducting acceptance activities based on the Inspection Standard used to conduct in-process acceptance activities for the Veress Needles. However, according to the investigator, your firm’s quality staff conducting the in-process acceptance activities were not familiar with the testing process and stated there were no established in-process acceptance procedures for the connection bond and puncture testing. However, in the Semi-Finished Inspection Record ((b)(4)), there is a requirement included to conduct a connection bond test and puncture test, that the quality staff conducting the in-process acceptance activities were not familiar with. The requirement listed in the semi-finished inspection record was not included in the final Veress Needle Quality Inspection Standard.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021, and have concluded it is not adequate. You plan to modify the Veress Needle Quality Inspection Standard and all other quality inspection standards, train relevant personnel of the quality and production department according to the revised Quality Inspection Standards, and perform retrospective review for all products which had been sold for the U.S market, to analyze if there is any quality issue or adverse event occurred. These actions have not been completed. In addition, your firm has not identified plans to evaluate their document control system, to make changes to ensure the requirements are consistent across documents. To ensure conformance to the standard across all relevant in-process acceptance activities, you should evaluate your document control system as part of your corrective action plan.\n\n7. Failure to adequately establish and maintain procedures to ensure that DHR's for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR, and the requirements of this part as required by 21 CFR 820.184\n\nFor example: Your firm was not able to provide Device History Records for their manufactured medical devices intended and exported to the US market. Your firm was unfamiliar with FDA regulations and requirements for manufactures to include the DHR requirements and their Device History Record Control Procedures (Doc No. (b)(4), Ver. (b)(4) and dated (b)(4)).\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You state you intend to modify their DHR control procedures based on the requirements of 21 CFR 820.184 and perform sample inspection of (b)(4) batches of the subject device based on the revised procedure, to confirm the integrity and correctness of the DHRs. You also plan to train relevant personnel on design, purchasing, quality, production, warehouse, logistics, PMC, and sales department according to the revised procedures and your firm plans to perform a retrospective review for all products which had been sold for the US market. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\n\n8. Failure to maintain device master records (DMRs) as required by 21 CFR 820.181.\n\nFor example: Your firm has not maintained their Device Master Records related to the subject device, and the personnel was unfamiliar with documents, processes, and medical devices related to the U.S market. Additionally, the manager of the site was not familiar with the FDA regulatory requirements to include DMRs for medical device manufacturers.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to output DMRs according to the reorganized Device History File for all products exported and intended for the U.S market, and to retrospectively review for all products which have been sold for the US market, to analyze if there are any quality issues or adverse events that have occurred. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\n\nGiven the serious nature of the violations of the Act, Veress Pneumoperitoneum Needles manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as 'detention without physical examination,' until these violations are corrected. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and correct the violations described in this letter. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed.\n\nYour firm's response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response. Please provide a translation of documentation not in English to facilitate our review.\n\nYour firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\n\nFood and Drug Administration - CDRH\u002FORP\u002FDRP2\n\nCDRH Regulatory Inspections and Audit Team, WO66-1434\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to CMS case #424228 when replying. If you have any questions about the contents of this letter, please contact: OHT Assistant Director, Jason Roberts at jason.roberts@fda.hhs.gov or (240)402-6400\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely Yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nOffice Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nZeyu Chen\n\n238 Fernwood Ave, Edison, NEW JERSEY 08837","Unimicro Medical Systems-Shenzhen Co., Ltd.","unimicro-medical-systems-shenzhen-co-ltd-624560-01062022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funimicro-medical-systems-shenzhen-co-ltd-624560-01062022","2026-10-26T08:10:17.543342+00:00","2022-03-22","624560","2023-05-31","Roly Lee","2026-08-20T02:05:33.087+00:00","VIA UNITED PARCEL SERVICE","2022-01-06",9,{"510k":198,"classification":199,"enforcement":200,"event":201,"event_backfill":202,"pma":203,"warning_letter":204},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]